Molecular pathways important for the pathogenesis and risk stratification of childhood T-ALL by Kox, Corinne
  
 
 
 
 
 
 
 
DISSERTATION 
 
SUBMITTED TO THE  
COMBINED FACULTIES FOR THE NATURAL SCIENCES AND FOR 
MATHEMATICS  
OF THE  
RUPERTO-CAROLA UNIVERSITY OF HEIDELBERG, GERMANY 
FOR THE  
DEGREE OF DOCTOR OF NATURAL SCIENCES 
 
 
 
 
 
 
 
 
 
 
 
 
PRESENTED BY 
 
CORINNE KOX -MASTER BIOLOGY 
BORN IN LUXEMBOURG, LUXEMBOURG 
 
ORAL EXAMINATION: 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
MOLECULAR PATHWAYS IMPORTANT FOR THE 
PATHOGENESIS AND RISK STRATIFICATION OF 
CHILDHOOD T-ALL 
 
 
 
 
 
 
 
 
 
 
 
 
REFEREES: 
 
DR. Andreas Ladurner 
PROF. DR. Christof Niehrs 
 
 
 
  
Summary 
 
 Paediatric T-cell acute lymphoblastic leukaemia (T-ALL) is a rare type of cancer that 
represents 10-15% of ALL cases. Intensified chemotherapy led to improvements of the overall 
survival rates of childhood T-ALL, reaching approximately 80%. However, the prognosis of 
relapses remains poor, emphasising the need for new molecular markers that identify high risk 
patients in the earliest stages of the disease. In addition, understanding of the precise 
mechanisms of T-ALL leukaemogenesis allows for the development of molecular targeted 
therapies that could potentially improve the quality of life of children with T-ALL, in general, and 
the response in patients that develop recurrent disease, in particular. Frequent genetic 
abnormalities in T-ALL are mutations in the NOTCH pathway which are thought to drive T-ALL 
development. 
In the first part of this study, the prognostic and predictive value of mutations in the NOTCH 
pathway was investigated in T-ALL patients, at initial presentation and at relapse. Activating 
mutations in the NOTCH1 gene and inactivating mutations in the FBXW7 gene, encoding for a 
negative regulator of the pathway, were correlated with early treatment response and long-term 
outcome. At initial presentation, NOTCH1 mutated patients treated according to the ALL-BFM 
2000 protocol show improved early treatment response and better long-term outcome. 
Interestingly, the NOTCH1 effect is restricted to the ALL-BFM 2000 good responders only. In the 
high risk group, patients with and without NOTCH1 mutations do not show a significant difference 
in long-term outcome. In contrast, inactivation of the FBXW7 protein correlates with excellent 
early response, but does not associate with better long-term outcome. At relapse, event-free 
survival rates were low in the ALL-REZ 2002 study, not exceeding 40%. In particular, FBXW7 
mutated patients with recurrent disease showed a poor response to treatment. This study laid 
foundations for the possible application of molecular markers in T-ALL risk stratification. 
In the second part of this PhD work, the effect of up-regulated NOTCH signalling on microRNA 
expression was analysed to gain insight into the pathogenic mechanisms of NOTCH1 in T-ALL. In a 
cell-based assay, NOTCH1 was knocked down in a T cell line and mature microRNA expression was 
monitored by microarray profiling. Two normalisation methods were employed for the microarray 
analysis. The first method identified 5 microRNAs down-regulated upon NOTCH1 knock-down, 
including members of the miR-17~92 and miR-106~363 clusters. However, no major changes in 
miRNA expression were observed when using the second normalisation method. The validation 
of the microarray experiments by microRNA-specific quantitative PCR confirmed the results from 
the second microarray normalisation method. In comparison, a qPCR approach detected a down-
regulation of primary microRNA transcripts, such as the transcript of the miR-17~92 cluster. In a 
  
second setting, the effect of NOTCH1 mutations on microRNA expression was determined in 
primary T-ALL patient samples. Marginal differences in expression were detected in members of 
the miR-17~92 cluster and the miR-181 family. Further work will be required to elucidate the 
mechanism of action of miRNA regulation by NOTCH1 in T-ALL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Zusammenfassung 
 
 Die T Zell lymphoblastische Leukämie (T-ALL) ist ein seltener Krebstyp, der meistens bei 
Kindern auftritt, und nur 10-15% der ALL ausmacht. Die Krankheit zeichnet sich in den letzten 
Jahren durch immer höhere Überlebenschancen aus. Eine Ausnahme stellen rezidivierte Patienten 
dar, weswegen die Früherkennung von Hochrisikopatienten und deren schnelle intensive 
Therapie besonders wichtig  ist. Eine individuelle Behandlung ab der Diagnose könnte die 
Überlebensrate der Hochrisikopatienten verbessern. Um die Diagnose des Rezidivrisikos sicher 
vorhersagen zu können, fehlen allerdings zuverlässige Marker. Des Weiteren ist es wichtig die 
Mechanismen der Pathogenese der T-ALL besser zu verstehen und hierauf aufbauend 
zielorientierte Therapien zu entwickeln. Individuelle Behandlungen könnten die Lebensqualität 
der Kinder mit T-ALL, und auch speziell das Therapieansprechen von rezidivierten Patienten 
verbessern. Häufige genomische Veränderungen in der T-ALL sind Mutationen im NOTCH 
Signalweg, die auch mitverantwortlich sind für die Entwicklung der Leukämie. 
Im ersten Teil der vorliegenden Studie wurden die Mutationen in Genen des NOTCH-Signalweges 
mit der Prognose der T-ALL Patienten korreliert. NOTCH1 enthält aktivierende Mutationen in 50% 
der Patienten, während FBXW7, ein Repressor von NOTCH1, inaktiviert wird durch Mutationen in 
weniger als 20% der T-ALL Patienten. Diese Mutationen wurden verglichen mit dem Ansprechen 
auf die Therapie, sowie mit dem Langzeitergebnis in der Erstdiagnose und im Rezidiv. In der 
Erstdiagnose der ALL-BFM 2000 Studie konnte ein positiver Effekt von NOTCH1 Mutationen auf 
das Therapie- und das Lanzeitergebnis nachgewiesen werden. Der NOTCH1-Effekt konnte lediglich 
in den Patienten festgestellt werden, die gut auf die Therapie angesprachen. In der Gruppe der 
Hochrisikiopatienten übte die NOTCH1 Mutation keinen Unterschied auf die Überlebensrate aus. 
Inaktivierende FBXW7 Mutationen korrelierten auch mit exzellentem Ansprechen der Patienten, 
es konnte allerdings keine Assoziation zwischen diesem Typ Mutation und eines verbesserten 
ereignisfreiem Überleben festgestellt werden. In Übereinstimmung mit den Erwartungen, 
überschritt die Überlebensrate bei rezidierten Patienten der ALL-REZ 2002 nicht mehr als 40%. 
Insbesondere Patienten mit FBXW7 Mutationen schlugen allgemein schlecht auf die 
Rezidivtherapie an. Diese Studie hat den Grundstein für den möglichen klinischen Gebrauch von 
Mutationen des NOTCH Signalweges gelegt. 
Im zweiten Teil dieser Studie wurde der Effekt von NOTCH1 Mutationen auf die Expression von 
microRNAs untersucht, um die Konsequenzen der NOTCH1 Aktivierung zu verstehen. In einem 
Zell-basierten Assay, wurde NOTCH1 in einer T-Zelllinie herabreguliert und die Expressionsprofile 
von reifen microRNA-Molekülen mit einer Microarray-Analyse untersucht. Zwei 
Normalisierungsmethoden wurden für die Analyse angewendet. Die erste Methode identifizierte 
  
5 microRNA-Moleküle, die herabreguliert waren, darunter Mitglieder der miR-17~92 und miR~106-
363 Cluster. Eine zweite Normalisierung konnte dagegen keinen Unterschied in den 
Expressionsprofilen von Kontroll- und NOTCH1-herabregulierten Experimenten aufzeigen. Die 
spezifische Amplifizierung der microRNA-Kandidaten durch quantitative PCR (qPCR) bestätigte 
die Resultate der zweiten Normalisierungsmethode, da keine Unterschiede in der Expression der 
microRNA-Moleküle entdeckt werden konnten. Die qPCR-Analyse konnte allerdings zwei primäre 
microRNA-Transkripte identifizieren, die nach einer Herabregulation von NOTCH1 ebenfalls 
herabreguliert waren: die Transkripte des miR-17~92-und des miR-491-Clusters. Zusätzlich wurden 
microRNA-Profile von T-ALL-Erstdiagnoseproben auf den Effekt von NOTCH1 Mutationen 
überprüft. Marginale Unterschiede in der Expression von microRNA-Molekülen aus dem miR-
17~92-Cluster und der miR-181-Familie wurden ermittelt. Zukünftige Studien werden notwendig 
sein, um die genauen Mechanismen der miRNA-Regulation von NOTCH1 in T-ALL zu untersuchen. 
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1. Introduction 
 
1.1 Paediatric T-cell acute lymphoblastic leukaemia 
In the human bone marrow (BM) reside the haematopoietic stem cells (HSCs) that give 
rise to all cellular blood components (Wilson and Trumpp, 2006). These stem cells comprise only 
0.01-0.05% of the total bone marrow population, but the number of HSCs remains constant due to 
their ability of self-renewal (He et al., 2009). The division of HSCs is asymmetrical giving rise to a 
new pool of HSCs and to the haematopoietic progenitor cells (HSPs). The formation of mature 
and functional blood cells is owed by the property of pluripotency of the HSCs. HSPs divide 
several times in a symmetrical fashion, and with every division become increasingly committed to 
one of two blood cell lineages, the myeloid or the lymphoid lineage. The common myeloid 
progenitors (CMP) will differentiate towards erythrocytes, megakaryocytes or towards 
monocytes, macrophages and granulocytes (neutrophils, eosinophils and basophils), whereas 
from the common lymphoid progenitors (CLP) T cells, B cells and Natural Killer (NK) cells are 
formed (Figure 1.1). The final maturation of all blood cells takes place in the BM, except T cells that 
mature in the thymus.  
Many regulatory processes in haematopoiesis are involved in the generation of sufficient and 
functional mature blood cells of all types. Deregulation of differentiation and development of 
these cells results in haematological disorders and cancer. Leukaemia, a type of haematological 
malignancy, is characterised by uncontrolled proliferation of immature white blood cells and 
impairment of their differentiation. The accumulation of leukaemic cells in the BM impairs the 
production of normal blood cells causing a deficiency in red blood cells (anaemia, reduced 
oxygenation), a deficiency in platelets (thrombocytopenia, internal bleeding) and a deficiency in 
normal white blood cells (increased risk for infections). In addition, leukaemic blasts can spread 
into the peripheral circulation which eventually leads to organ infiltration. Without treatment, 
leukaemia is a fatal disease. 
Depending on the lineage origin of the leukaemic blasts, one differentiates between lymphoid or 
myeloid leukaemia. Lymphoid leukaemias are further subdivided into T- or B-lineage leukaemias. 
Another subdivision differentiates between the acute and chronic forms of leukaemia. Acute 
leukaemia is characterised by a rapid accumulation of immature leukaemic blasts and occurs 
mainly in children and young adults. In chronic leukaemia, the proliferation of blasts is slower, and 
the cells are characterised by a more mature differentiation state. The chronic form occurs mostly 
in elderly people. The leukaemia classification consists of 4 main categories: acute lymphoid 
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leukaemia (ALL), chronic lymphoid leukaemia (CLL), acute myeloid leukaemia (AML), chronic 
myeloid leukaemia (CML). 
 
 
Figure 1.1 Simplified schematic representation of the human haematopoiesis  
(HSP, haematopoietic stem cell; CMP, common myeloid precursor; CLP, common lymphoid 
precursor)  
 
 
In children, leukaemias represent the most common type of cancers. The ALL form represents the 
most common leukaemia with around 85% of the cases (Pui et al., 2004). The age peak of 
paediatric ALL occurs between 2 and 5 years. Interestingly, more boys than girls are affected by 
ALL (Van Vlierberghe et al., 2010). 10-15% of ALLs represent T-ALL, a particularly aggressive form of 
leukaemia with a high white blood cell (WBC) count at diagnosis. T-ALL is triggered by the 
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proliferation of immature thymoblasts. In T-ALL, leukaemic thymoblasts can be arrested at 
different intrathymic maturation stages. Immunophenotyping by using common cell surface 
markers helps to distinguish between the maturation stages. There are 4 main phenotypes: pro-T, 
pre-T, cortical and mature phenotype (Bene et al., 1995). The main treatment strategies include 
intensive chemo- and radiotherapy (Conter et al., 2010). The introduction of these new 
therapeutic strategies has substantially improved the treatment outcome of paediatric T-ALL 
patients. However, relapses are usually fatal due to therapy-resistance. Compared to childhood T-
ALL, adult T-ALL remains a difficult cancer to cure with survival rates between 40-60% (Heesch et 
al., 2010; Marks et al., 2009). Although, the outcome in childhood T-ALL has improved drastically, 
individualised treatment approaches would be desirable for the cure of patients with high relapse 
risk. In addition, reduction of therapy intensity for good responders could diminish treatment-
related toxicity and severe long-term sequelae.  
A study group that was involved in major advances in paediatric ALL treatment is the multi-centre 
study group, ALL-BFM (Berlin/Frankfurt/Münster), founded in Germany. The ALL-BFM treatment 
protocol is applied in more than 70 hospitals in Germany, Austria and Switzerland. The latest 
protocol with a long follow-up (ALL-BFM 2000) is divided into 4 blocks, the induction phase, the 
consolidation phase, the re-induction phase and the maintenance. Each patient undergoes a pre-
phase which includes the administration of prednisone (or dexamethasone) and intrathecal 
methotrexate. After the induction phase, patients are stratified into one of three risk groups 
dependent on their early treatment response, assessed by prednisone response on day 8 and by 
minimal residual disease (MRD) kinetics on days 33 and 78. Prednisone response corresponds to 
the direct count of blasts in the blood. Patients with less than 1000 blood blasts/μL were defined 
as prednisone good responders (PGR), whereas those with 1000 or more blood blasts/μL were 
considered as prednisone good responders (PPR) (Dordelmann et al., 1999). MRD quantification 
is carried out by allele-specific detection and amplification of leukaemic clonal immunoglobulin 
(Ig) and T-cell receptor (TCR) gene rearrangements using the quantitative polymerase chain 
reaction (PCR) technique (Szczepanski et al., 2002a). 
The three risk groups correspond to  
- the standard risk (SR) group defined by a prednisone good response (PGR) and negative 
MRD results on days 33 and 78; 
- the high risk (HR) group defined by a prednisone poor response (PPR), a MRD response of 
≥10-3 on day 78, or both; 
- and the intermediate risk (MR) group which regroups all remaining patients. 
Importantly, all T-ALL patients are given prophylactic cranial irradiation to prevent CNS relapse. 
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T-ALL patients, that suffer a relapse, undergo intensified treatment with chemotherapy, 
radiotherapy and, in most cases, allogeneic stem-cell transplantation (Tallen et al., 2010).  
 
The aetiology of leukaemia is still under debate, and only rare reports describe a familial 
occurrence. Hypotheses of what causes leukaemia include environmental factors or infections 
(Greaves, 2006). Molecular insight into the genetic causes of T-ALL was gained by the discovery of 
abnormal karyotypes in about 50% of the patients (Graux et al., 2006). Chromosomal 
translocations frequently involve fusions of the TCR genes with genes involved in transcription 
regulation, such as TAL1, HOX11, LYL1, LMO1, LMO2 or NOTCH1 resulting in their ectopic expression 
(Graux et al., 2006). Non-TCR translocations result in the generation of fusion genes with 
oncogenic properties encoding chimeric proteins like SIL-TAL1. These chromosomal translocations 
result from illegitimate TCR rearrangements during T cell development. Other genetic loci could 
also be prone to recombination when present in an open chromatin configuration. Interestingly, 
some diagnosed ALL patients have already harboured chromosomal abnormalities prenatally 
which, in combination with further genetic events, induce leukemogenesis at a later age (Gale et 
al., 1997; Greaves et al., 2003). Even in the absence of chromosomal abnormalities, these T cell 
oncogenes are often aberrantly expressed (Ferrando et al., 2002). Other genomic abnormalities 
have been identified by genomic profiling including amplifications or deletions affecting 
transcription factor genes (MYB, LEF1) and genes involved in signalling pathways (PTEN 
(Phosphatase and Tensin homolog)), cell cycle progression (CDKN1B, CDKN2A, CDKN2B) and 
apoptosis (CASP8AP2) (Burkhardt et al., 2008; Lahortiga et al., 2007; Mullighan et al., 2007; Remke 
et al., 2009). Furthermore, epigenetic silencing is affected in T-ALL, involving hypermethylation of 
promoter regions (Dunwell et al., 2010; Dunwell et al., 2009; Roman-Gomez et al., 2005). 
Moreover point mutations have been found in NOTCH1 (>50% of the patients), in its negative 
regulator, FBXW7 (15-30%), in genes involved in the PI3K-Akt (phosphatidyl-inositol-3-kinase) 
pathway (Gutierrez et al., 2009; Jotta et al., 2010; Remke et al., 2009), in a transcriptional 
regulator, PHF6 (Van Vlierberghe et al., 2010), and less frequently in a receptor tyrosine kinase, 
FLT3 (Van Vlierberghe et al., 2005).  
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1.2 The NOTCH pathway in paediatric T-ALL 
 
1.2.1 NOTCH1, a transmembrane receptor with a transcription activating function 
 
1.2.1.1. The structure and the function of NOTCH1  
NOTCH mutants were first described in Drosophila melanogaster that carried notches in 
the wing blades (Morgan, 1917). Later this phenotype was described to be the result of a 
haploinsufficiency of the gene NOTCH (Kidd et al., 1986; Wharton et al., 1985). NOTCH is a family 
of evolutionary conserved type I transmembrane receptors. In mammals four different NOTCH 
receptors (NOTCH1-NOTCH4) and five corresponding ligands (Delta-like1 (Dll1), Dll3, Dll4, Jagged1 
(J1), and J2) are found.  
NOTCH is a transmembrane receptor which contains 2 subunits, an extracellular and a 
transmembrane subunit (Figure 1.2). These two subunits are associated non-covalently through 
the heterodimerisation domains in a Ca2+-dependent manner. The extracellular part contains 
epidermal growth factor (EGF)-like repeats including ligand binding sites, followed by three 
cysteine-rich Lin12-Notch (LIN) repeats that are involved in preventing NOTCH signalling in the 
absence of a ligand. The transmembrane part contains in the intracellular region: 
- RBPJk-associated molecule (RAM) region in the juxtamembrane region harbouring a  
binding site for CSL (CBF1, Suppressor of Hairless, Lag-1), a DNA-binding transcription 
factor; 
- six ankyrin repeats involved in docking of CSL and members of the MAML (Mastermind-
like) family, transcriptional coactivators; 
- transactivation domain (TAD);  
- PEST (Proline-Glutamate-Serine-Threonine rich) domain involved in the degradation of the 
intracellular part. This domain contains a WSSSSP motif and a Cdc4 phospho-degron 
(CPD) which is recognised by the E3 ubiquitin ligase FBXW7 (see 1.2.2). Both motifs are 
involved in NOTCH1 ubiquitylation (Chiang et al., 2006; Thompson et al., 2007). 
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Figure 1.2 The transmembrane receptor NOTCH1 and its domains. 
LIN (Lin12-Notch), HD (Heterodimerisation domain), TM (Trans-membrane domain), RAM 
(RBPJk-associated molecule), TAD (Transactivation domain), PEST Proline-Glutamate-
Serine-Threonine rich domain) 
 
 
For proper function, NOTCH1 has to undergo post-translational modifications. The O-fucosyl 
transferase (O-Fut) adds a first fucose on the glycosylation sites located in the EGF-like domains 
(Figure 1.3). O-Fut is also essential for the proper folding and transport of NOTCH to the plasma 
membrane. Other glycosyl-transferases (members of the Fringe family) elongate the 
carbohydrate chains in the EGF-like domains. Interestingly, differential glycosyl-modifications 
generate NOTCH molecules with different ligand binding affinities. Another important 
modification is the S1 cleavage by the furin-like convertase, which generates the extracellular and 
the transmembrane parts of NOTCH1 (Blaumueller et al., 1997; Logeat et al., 1998). The activation 
of the transmembrane receptor is triggered by specific Delta-like or Jagged ligands to the 
extracellular part of NOTCH1. Binding of the ligand to the EGF-like repeats triggers two successive 
cleavages which in turn cause the release of the intracellular part of NOTCH1 (ICN1) into the 
cytoplasm. The first activating cleavage (S2) involves the ectodomain of NOTCH and is dependent 
on a metalloprotease of the ADAM/TACE/Kuzbanian family (Brou et al., 2000). The second 
activating cleavage (S3) within the TM is catalysed by the γ-secretase complex (Mumm et al., 
2000). This complex is necessary to release the intracellular portion of NOTCH1 into the cytoplasm 
from where it is translocated into the nucleus. When in the nucleus, ICN1 interacts with a 
transcription factor, CSL, and transcriptional coactivators from the MAML family. In the absence 
of ICN1, CSL is associated to transcriptional co-repressors and inhibits the expression of NOTCH1 
target genes. The association of ICN1 and CSL, however, results in the release of CSL from the 
repressors, probably due to a conformational change. CSL, when bound to ICN1, will then act as a 
positive transcriptional regulator. The ICN1/CSL/MAML complex is able to activate the 
transcription of NOTCH1 target genes. Although, a CSL-independent signalling of NOTCH has been 
proposed, the underlying mechanism is so far unknown (Martinez Arias et al., 2002). The 
termination of NOTCH signalling is achieved by ICN1 degradation. CDK8 phosphorylates NOTCH1 
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rendering it susceptible for ubiquitylation by FBXW7, which is an E3 ubiquitin ligase. FBXW7 
specifically binds and ubiquitinates a CPD within the PEST domain. Furthermore, the WSSSSP 
motif is also required for efficient degradation, but the potential kinases phosphorylating the 
serine residues have not been identified yet.  
 
 
Figure 1.3 The NOTCH1 pathway 
 
1.2.1.2 The role of NOTCH1 in haematopoiesis 
The NOTCH pathway functions broadly; it is involved in lateral inhibition (Greenwald, 
1998), lineage decisions (Hartenstein and Posakony, 1990; Louvi and Artavanis-Tsakonas, 2006), 
and forming boundaries or niches (Bray, 1998). The developmental and physiological processes in 
which the NOTCH pathway is involved are very diverse. In mammals, essential functions of NOTCH 
occur at various stages in haematopoiesis (Radtke et al., 2010). NOTCH receptors and their ligands 
are widely expressed in the haematopoietic system. During murine embryonic development, 
NOTCH1 signalling is required for the generation of HSCs (Kumano et al., 2003). The best 
characterised NOTCH function in haematopoiesis is its role during lymphoid development, and 
specifically during thymic T cell lineage commitment and maturation (Radtke et al., 2004; Tanigaki 
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and Honjo, 2007). Various NOTCH receptors and ligands are expressed in lymphoid progenitors, 
suggesting redundant and non-redundant functions (Kitamoto et al., 2005). Specifically, NOTCH1 
was reported to be necessary and sufficient to specify T cell fate. Bone marrow progenitors 
depleted of NOTCH1 launch a B lymphoid program when entering the thymus, whereas 
constitutively active NOTCH1 in these cells causes an ectopic production of immature T cells at the 
expense of B cells (Pui et al., 1999; Radtke et al., 1999; Wilson et al., 2001). In early T lineage 
precursors (ETPs) NOTCH signalling is still required as these cells maintain their non-T cell 
potential (Bell and Bhandoola, 2008; Feyerabend et al., 2009). Interestingly, although weak 
NOTCH activity is able to suppress B lineage development, it is not sufficient to induce T cell 
development (Hoebeke et al., 2006; Schmitt et al., 2004; Visan et al., 2006). Altogether, these 
data suggest that the NOTCH pathway is used to target different genes depending on the amount 
of activated NOTCH1 molecules.  
 
1.2.1.3 The role of NOTCH1 in paediatric T-ALL 
Tight regulation of the duration of NOTCH signalling and the identity of its targets is 
important for the proper development and function of cells and tissues. Deregulation of its 
activity is, not surprisingly, implicated in the pathology of several malignant diseases, including 
paediatric T-cell acute lymphoblastic leukaemia (T-ALL). The first indication of NOTCH1 function in 
T-ALL came with the identification of a chromosomal translocation, t(7;9) (q34:q34.3), involving 
the juxtaposition of the NOTCH1 gene on chromosome 9 to the TCRB locus on chromosome 7 
(Ellisen et al., 1991; Reynolds et al., 1987). Interestingly, only the intracellular part of NOTCH1 is 
juxtaposed to the promoter, and enhancer sequences of the TCRβ receptor gene induce an 
overexpression of a constitutively active NOTCH1. In murine models, constitutive activation of 
NOTCH1 causes aggressive T-ALL, providing evidence of its oncogenic function (Pear et al., 1996). 
However, the t(7;9) chromosomal translocation occurred in a minor fraction of children with T-
ALL (<1%). Later Weng et al. described activating mutations in NOTCH1 in over 50% of all T-ALLs 
(Weng et al., 2004). Most of these mutations lie in the heterodimerisation domains which are 
hypothesised to reduce the affinity between the two subunits. This would lead to ligand-
independent cleavage of the transmembrane subunit. Some other mutations cause a premature 
stop codon in the TAD or the PEST domain, resulting in an increase of the stability of ICN1 due to 
the absence of the degradation signal. Both, the translocations and the mutations are thought to 
result in an aberrant activation of NOTCH1 and an increase of its activity.  
An important research focus became the identification of possible target genes of NOTCH1. 
Several studies reported an up-regulation of c-Myc upon ectopic NOTCH1 expression, and 
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identified the MYC gene as a direct transcriptional target of NOTCH1 (Palomero et al., 2006; 
Sharma et al., 2006; Weng et al., 2006).  Another finding represents the transcriptional activation 
of the IκB kinase complex, thereby inducing the activation of the NF-κB (nuclear factor 'kappa-
light-chain-enhancer' of activated B-cells) pathway (Vilimas et al., 2007). Phosphorylation specific 
protein microarrays detected the mTOR (mammalian Target of Rapamycin) pathway as a 
positively regulated target of NOTCH1 (Chan et al., 2007). How this effect is mediated, is only 
partially understood. In addition, aberrant NOTCH1 signalling has a direct effect on cell cycle 
progression by inducing the proteasome-mediated degradation of CDKN1B, a cyclin-dependent 
kinase inhibitor, and the expression of SKP2, the S phase kinase-associated protein 2 (Dohda et al., 
2007). It was shown that both CDKN1B and CDKN2D are induced in T-ALL cell lines treated with γ-
secretase inhibitors (GSI) (Rao et al., 2009). Furthermore, in mice with aberrantly expressed 
NOTCH1, p53 is suppressed  through an ARF-mdm2-p53 mechanism, which led to inhibition of 
apoptosis (Beverly et al., 2005). Moreover, upon ectopic NOTCH1 expression, a signaling protein 
with anti-apoptotic functions, GIMAP5 (GTPase of immunity-associated nucleotide binding protein 
5), was shown to be up-regulated (Chadwick et al., 2009). Additionally, NOTCH1 induces the 
expression of a chemokine receptor, CCR7 (CC-chemokine receptor 7), in T-ALL, which is essential 
for CNS infiltration (Buonamici et al., 2009). In summary, aberrant NOTCH1 signalling affects cell 
growth, survival and tissue infiltration of T cells by interfering with various molecules and 
pathways. 
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Figure 1.4 Targets of the aberrant NOTCH1 activation in T-ALL 
 
 
 
1.2.2 FBXW7, a negative regulator of the NOTCH pathway 
FBXW7 (F-box and WD repeat domain-containing 7), an E3 ubiquitin ligase, is a component 
of the SCF complex (SKP1, CUL1 and F-box protein) that is responsible for the ubiquitylation of 
proteins destined for proteasomal degradation. FBXW7 was first described in genetic screens in 
budding yeast as Cdc4 (Hartwell et al., 1973). Cdc4 controls the cell cycle checkpoint by causing 
the disposal of cyclin-dependent kinase (CDK) inhibitor, Sic1 (Feldman et al., 1997; Verma et al., 
1997). The human FBXW7 gene is located on chromosome 4, and is able to produce three different 
transcripts by alternative splicing, FBXW7α, β and γ. These isoforms vary only in their N-terminal 
sequence and are in principle functionally identical. However, they occupy different cellular 
locations (Kimura et al., 2003; Welcker et al., 2004). FBXW7α and γ contain both a NLS (nuclear 
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localisation signal) and are localised in the nuclear and in the nucleolar region, respectively. 
FBXW7β contains a TMD (transmembrane domain) and is found in a cytoplasmic distribution. The 
FBXW7 protein contains three major domains, a dimerization domain (DD), an ubiquitin ligase (F-
box) and 8 repeats of WD domains (WD40). The F-box domain interacts with Skp1 from the SCF 
complex (Bai et al., 1996), whereas the WD40 domains mediate substrate binding by specific 
recognition of a phospho-epitope, called Cdc4 phospho-degron (CPD) (Hao et al., 2007). 
Homodimerisation of FBXW7 seems to be dispensable for ubiquitylation of some substrate 
proteins, and may depend on the strength of binding to the CPD in the substrate. FBXW7 targets 
some of the most broadly acting proteins for degradation, these include MYC, PSEN1, c-JUN, 
cyclin E1, SREBP (sterol regulatory element-binding protein), mTOR or Aurora-A (Koepp et al., 
2001; Li et al., 2002; Mao et al., 2004; Nateri et al., 2004; Sundqvist et al., 2005; Yada et al., 2004). 
Noticeably, FBXW7 regulates several proteins within the NOTCH pathway, including NOTCH1, the 
γ-secretase complex, PSEN1 (presenilin1), and several NOTCH1 downstream effectors, like c-MYC 
or mTOR.  
 
 
Figure 1.5 The E3 ubiquitin ligase FBXW7 and its domains. 
FBXW7 contains a dimerisation domain (D domain), an ubiquitin ligase function (F-box 
domain) and 8 repeats of the WD40 domains involved in substrate binding. 
 
FBXW7 null mice die in utero at embryonic day 10.5-11.5 of gestation because of defective 
cardiovascular and hematopoietic development. In these mice, an accumulation of NOTCH led to 
increased expression of NOTCH pathway downstream effectors (Tetzlaff et al., 2004; Tsunematsu 
et al., 2004). It was reported that a specific loss of FBXW7 in the HSCs resulted in their premature 
depletion due to active proliferation and p53-induced apoptosis. When p53 was suppressed, most 
animals developed T-ALL (Matsuoka et al., 2008). In mice with a conditional FBXW7 deficiency in 
the T cell lineage, immature T cells hyper-proliferate whereas mature T cells show a cell-cycle 
arrest followed by p53-dependent apoptosis (Onoyama et al., 2007).  
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Not surprisingly, it was discovered that FBXW7 is deregulated in several human malignant 
diseases by chromosomal aberrations or point mutations, e.g. endometrial cancer (Spruck et al., 
2002), colorectal cancer (Rajagopalan et al., 2004) or T-ALL (Maser et al., 2007). The highest 
mutational incidence was found in cholangiocarcinoma (35%) (Akhoondi et al., 2007). In T-ALL, 
FBXW7 mutations were described in about 11-30% (Akhoondi et al., 2007; Larson Gedman et al., 
2009; Maser et al., 2007). The heterozygous mutations found in FBXW7 are inactivating missense 
or nonsense mutations. Of interest, T-ALL contains mostly missense mutations. The mode of 
action of the mutated FBXW7 proteins varies depending on the location of the mutation. Most 
missense mutations target arginine residues in the WD40 region that mediate specific substrate 
binding. The D domain however, stays intact, and by dimerisation with a functional FBXW7 
molecule, the truncated FBXW7 is hypothesised to function as dominant-negative. Nonsense 
mutations downstream of the D domain could also produce potential dominant-negative 
proteins, whereas stop codons upstream of the D domain likely produce non-functional alleles.  
Binding to NOTCH1 is mediated by a CPD in the PEST domain, a threonine residue located on 
position 2512. Most NOTCH1-PEST mutations in T-ALL interfere with this residue by directly 
mutating it or causing premature stop codons upstream of this region. Interestingly, only rarely a 
NOTCH1-PEST mutation is found in combination with a FBXW7 mutation. This almost complete 
mutual exclusivity suggests that the main target of FBXW7 in T-ALL is NOTCH1, and that no 
additional selection advantage is provided by combining a NOTCH1-PEST and FBXW7 double 
mutation (Maser et al., 2007; O'Neil et al., 2007). If also other target proteins are affected by 
FBXW7 mutations in T-ALL, is not known. 
 
1.3 MicroRNAs in paediatric T-ALL 
 
1.3.1 MicroRNA biogenesis 
Mature microRNAs (miRNAs) are single-stranded non-coding RNAs of 19-25 nucleotides in 
length that negatively regulate gene expression. Mature miRNAs are incorporated in a 
ribonucleoprotein complex (RISC complex). MiRNAs are predicted to be one of the largest gene 
families, counting for 1% of the total genome. The miRNA genes are mostly localised in intergenic 
regions, some in introns, protein-coding or non-coding (in the sense or antisense orientation) 
regions. Often, miRNA genes encode for multiple miRNAs, the so-called miRNA clusters that form 
polycistronic transcription units. MiRNAs exist in animals, plants and viruses, but have not been 
identified in yeast. 
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MiRNAs are transcribed as long primary transcripts (pri-miRNAs) by the RNA Polymerase II (PolII) 
(Figure 1.4). The pri-miRNAs contain a 5’ cap structure, one or more hairpin-loop structures as well 
as 3’ polyA tails (Cai et al., 2004; Lee et al., 2004). It is believed that the pri-miRNA tertiary 
structure determines the recognition by a microprocessor complex consisting of the RNase type 
III endonuclease, Drosha, and DGCR8 (DiGeorge syndrome critical region gene 8) (Denli et al., 
2004; Lee et al., 2003; Zeng and Cullen, 2003; Zeng et al., 2005). A 70-nucleotide long stem-loop 
RNA is cleaved, called the precursor-miRNA (pre-miRNA). MiRNAs are evolutionarily highly 
conserved in their stem sequence, but diverge consistently in the regions flanking the stem-loop 
(Kim, 2005). The Ran-GTP dependent exportin-5 is responsible for the active transport of the pre-
miRNA into the cytoplasm (Bohnsack et al., 2004; Lund et al., 2004; Yi et al., 2003). The 
cytoplasmic RNase III Dicer in association with TRBP (HIV-1 transactivating response (TAR) RNA 
binding protein) processes the pre-miRNA into a mature duplex miRNA (Hutvagner et al., 2001; 
Knight and Bass, 2001). Mostly only one strand is incorporated into the miRNA-containing RNA 
induced silencing complex (miRISC), whereas the second one is degraded. The single-stranded 
mature miRNA tends to be selected on the basis of the thermodynamic instability of the base 
pairs at the end of the duplex; the strand with the weaker 5’end base-pairing relative to the 
complement will preferentially be incorporated into miRISC (Khvorova et al., 2003; Schwarz et al., 
2003). This complex is composed of members of the highly conserved Argonaute (Ago) family 
and a number of other protein components with RNA binding or helicase activity (Sontheimer, 
2005). The mature miRNA finally mediates the binding of the miRISC with the target mRNA. In 
plants, most miRNAs condemn the mRNAs to destruction by cleavage and degradation by an 
almost perfectly complementary binding in a single site (Hake, 2003). In contrast, in animals 
multiple binding sites exist mainly in the 3’UTR region of the mRNA, but base-pairing is only 
partially complementary. Here the binding is mediated by an almost perfect annealing of the 
“seed” sequence embodied in the nucleotides 2 to 8 (Tomari and Zamore, 2005). In general, the 
fate of the target mRNA depends on the stability of the mRNA-miRNA base pairing; a perfect 
match causes the degradation of the mRNA (Hutvagner and Zamore, 2002), whereas partial 
complementarity represses its translation (Bartel, 2004). Up to date, how the translational 
repression is achieved remains elusive. Biochemical data show an association of miRNPs with 
polyribosomes suggesting an interference with protein synthesis (Nottrott et al., 2006). 
Alternative mechanisms include interference with the recognition of the 5’ cap to prevent 
translational initiation (Pillai et al., 2005; Thermann and Hentze, 2007), deadenylation of the polyA 
tail (Eulalio et al., 2009; Wu et al., 2006) and recruitment of eIF6, a ribosome inhibitory factor 
(Chendrimada et al., 2007). Moreover, colocalisation of Ago proteins with processing bodies (P 
bodies) lead to the hypothesis of miRNA-targeted mRNAs sequestration into P bodies which 
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show an accumulation of endonucleases and decapping proteins, but lack ribosomes and 
initiation factors (Liu et al., 2005; Sen and Blau, 2005). An interesting observation was described in 
cells entering quiescence in which miRNAs trigger a translational activation rather than a 
repression (Vasudevan et al., 2007). 
Regulation of miRNA biogenesis probably occurs mostly on the transcriptional level, as 
expression of miRNAs is controlled by methylation of the promoter region (Saito et al., 2006) and 
by transcription factors (He et al., 2007; O'Donnell et al., 2005). However, alternative mechanisms 
were proposed including pri-miRNA editing which can influence positively or negatively the 
cleavage by Drosha (Scadden, 2005; Yang et al., 2006), regulation of the Drosha-DGCR8 complex 
(Davis et al., 2008; Han et al., 2009) and regulation of the cleavage by Dicer (Forman et al., 2008; 
Rybak et al., 2008). Although miRNA degradation pathways have been identified in plants 
(Ramachandran and Chen, 2008), the mechanisms of miRNA half-life regulation in animals await 
further investigation.  
The latest release of the miRBase database lists more than 900 human miRNAs that have been 
identified by cloning and through computational analysis. Computational analyses estimate that 
20-30% of the genome might be regulated by miRNAs, and that on average any given miRNA 
might target up to 200 mRNAs (Lim et al., 2005). One of the biggest limitations in the functional 
analysis of miRNA is the lack of reliable tools for target prediction. Development of algorithms for 
miRNA-target prediction (i.e. target mRNAs) is rather difficult, because in mammals the miRNA-
mRNA recognition occurs through partial complementarity. Hence, target prediction always 
requires validation. A number of studies based on  different biochemical approaches not only 
validated miRNA targets, but also show that miRNA interference/overexpression has a 
widespread effect on post-translational gene regulation (Baek et al., 2008; Beitzinger et al., 2007; 
Easow et al., 2007; Karginov et al., 2007; Selbach et al., 2008).  
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Figure 1.6 MicroRNA biogenesis and function 
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1.3.2 MicroRNA in haematopoiesis  
MiRNAs are expressed during different developmental stages and in different tissues. 
They are involved in various processes, including cell proliferation and apoptosis, stem cell 
maintenance and cell fate specificity. Not only is their expression in time and space of importance, 
but also their expression levels need to be tightly regulated. 
Specifically in haematopoiesis, controlled miRNA expression is crucial for proper development of 
all blood cells. A functional role for miRNAs in haematopoiesis has previously been predicted, as 
miRNA genes are frequently found close to chromosomal breakpoints (Calin et al., 2004b). A 
general role for miRNAs in haematopoiesis was suggested as the conditional deletion of Dicer in 
murine lymphoid progenitors resulted in impaired T cell development (reduction of helper T cell 
proliferation and survival, reduction of regulatory T cells) (Cobb et al., 2006; Muljo et al., 2005) 
and in a block at the pro- to pre-B cell transition (Koralov et al., 2008). First indications of miRNAs 
involved in haematopoiesis came from studies describing the expression of individual miRNAs in 
the different haematopoietic compartments, including BM, thymus and peripheral blood (Chen et 
al., 2004; Monticelli et al., 2005). Interestingly, miRNA expression profiles differ not only between 
haematopoietic cell types, but are also temporarily regulated in the various developmental stages 
in haematopoiesis (Monticelli et al., 2005; Neilson et al., 2007). 
In lymphopoiesis, important miRNAs are miR-181, miR-142, miR-223, miR-150 and miR-17~92. miR-
181, highly expressed in thymocytes and mature B cells, has prominent functions in B cell 
development. Over-expression studies of miR-181 in murine HPCs showed an increase of B cells, 
but a reduction of the T cell lineage. Enforced expression of miR-223 and miR-142 resulted in an 
increased T cell number, and a modest effect on the myeloid lineage (Chen et al., 2004). An 
additional function of miR-181 is to positively regulate T cell sensitivity and selection (Li et al., 
2007). Murine B cell development is also substantially impaired when miR-150 is depleted or 
ectopically expressed (Xiao et al., 2007; Zhou et al., 2007). Similarly, depletion of the miR-17~92 
cluster inhibits B cell development by stabilisation of the pro-apoptotic protein, BIM (BCL-2-
interacting mediator of cell death; Ventura et al., 2008). Furthermore regulation of the T- and B-
cell responses is under the control of miR-155 expression. miR-155 knock-out mice were shown to 
be immunodeficient (Rodriguez et al., 2007; Thai et al., 2007). miR-155 also functions in dendritic 
cells by regulating the pathogen binding activity through the down-regulation of DC-SIGN (DC-
specific Intercellular Adhesion Molecule-3 Grabbing Non-integrin) (Martinez-Nunez et al., 2009) 
(Table 1.1). 
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Multiple links between myeloid development and miRNA expression have been proposed. miR-
223 has several roles during different stages of myeloid cell development by regulating 
granulocyte generation and function, in addition to modulating neutrophil sensitivity (Fazi et al., 
2005; Fukao et al., 2007; Johnnidis et al., 2008). Moreover, members of the miR-17~92 cluster and 
its homologue cluster miR-106~363 regulate monocyte proliferation and maturation (Fontana et 
al., 2007). Although not described in detail here, many other miRNAs seem to play an extensive 
role in myelopoiesis and in the innate immune response, such as miR-155, miR-146 or miR-221/222 
(Felli et al., 2005; Jurkin et al., 2010; O'Connell et al., 2008; O'Connell et al., 2007; Taganov et al., 
2006) (Table 1.1). 
miRNA 
Haematopoietic 
lineage 
Function References 
miR-181 lymphopoiesis 
regulates B cell development positively, but T cell 
development negatively; 
Chen et al., 2005 
modulates T cell sensitivity and selection Li etal., 2007 
miR-142 lymphopoiesis negatively regulates the T-lymphoid development Chen et al., 2005 
miR-150 lymphopoiesis 
inhibits B cell differentiation at the proB- to pre-B 
cell transition 
Xiao et al., 2007 
Zhou et al., 2007 
miR-106~363  myelopoiesis 
miR-106a inhibits monocytic differentiation and 
maturation 
Fontana et al., 2007 
miR-146 myelopoiesis 
role for miR-146 in control of Toll-like receptor and 
cytokine signalling; 
Taganov et al., 2006 
ectopic miR-146a expression influences DC 
sensitivity to PGN-induced activation 
Jurkin et al., 2010 
miR-221/222 myelopoiesis 
expression of miR-221/222 causes impaired 
proliferation and accelerated differentiation of 
erythropoietic cells 
Felli et al., 2005 
miR-223 
lymphopoiesis 
ectopic expression of miR-223 causes a 30 to 40% 
increase in the T-lymphoid lineage ; 
Chen et al., 2003 
myelopoiesis 
levels of miR-223 control the differentiation fate of 
promyelocytic precursors; 
Fazi et al., 2005 
delimits neutrophil production and activation 
Fukao et al., 2007 
Johnnidis et al., 2008 
miR-155 
lymphopoiesis 
involved in the in vivo control of specific 
differentiation processes in the immune response; 
Rodriguez et al., 
2007 
regulates the function and response of B and T 
lymphocytes, and of dendritic cells; 
Thai et al., 2007 
modulates pathogen binding ability in dendritic 
cells; 
Martinez-Nunez et 
al., 2009 
myelopoiesis 
important in the primary macrophage response to 
different types of inflammatory mediators 
O'Connell et al., 2007 
O'Connell et al., 2008 
miR-17~92 
lymphopoiesis 
in miR-17~92 deficient embryos a reduction in pre-B 
cells  was observed, due to increased apoptosis; Ventura et al., 2008 
regulates B cell survival; 
myelopoiesis 
miRNAs 17-5p and 20a inhibit monocytic 
differentiation and maturation 
Fontana et al., 2007 
 
Table 1.1 MicroRNAs involved in haematopoiesis 
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1.3.3 MicroRNA in cancer  
Given their important role in development, it is not surprising that deregulation of miRNA 
expression is involved in cancerogenesis. More than half of the known human miRNA genes are 
located near chromosomal breakpoints or cancer-associated genomic regions indicating an 
implication of miRNAs in leukaemogenesis (Calin et al., 2004b). Other than chromosomal 
aberrations, potential alternative causes for abnormal miRNA expression in cancer are the 
deregulation of miRNA processing mechanisms (Kumar et al., 2007; Kumar et al., 2009) and 
epigenetic deregulation of miRNA genes (Saito et al., 2006). Still under investigation is the role of 
relatively infrequent SNPs, mutations in miRNAs or mutations in miRNA seed sequences in target 
genes (Ryan et al., 2010). MiRNAs were shown to have tumour suppressor and/or oncogenic 
activity, which is dependent on the cell type and the pattern of expression (He et al., 2005; 
O'Donnell et al., 2005). The first evidence of tumour suppressor activity came from homozygous 
deletions in B-cell CLL involving two clustered miRNAs, miR-15 and miR-16 (Calin et al., 2002). 
Later, it was shown that the effect of the deletions is partly due to the stabilisation of the Bcl-2 
mRNA, encoding an anti-apoptotic protein (Cimmino et al., 2005). Given its extensive role in 
lymphoid and myeloid development, it is not surprising that the miR-17~92 and miR-106~363 
clusters are involved as oncogenes in B-cell lymphomas, in CML and in T-cell leukaemia (He et al., 
2005; Landais et al., 2007; Mavrakis et al., 2010; Ota et al., 2004; Venturini et al., 2007).  
High throughput methods such as miRNA expression profiling have been useful to determine 
candidate miRNAs directly involved in tumourigenesis. These techniques might also serve to 
identify miRNA signatures with diagnostic and prognostic implications. Diagnostic utility of 
circulating miRNAs in serum was described in patients with diffuse large B-cell lymphoma (miR-
155, miR-210, miR-21) and ALL (miR-16) compared to a healthy cohort (Kaddar et al., 2009; Lawrie 
et al., 2008). MiRNA patterns differ between tumour entities, and between different subclasses 
of the same tumour type (Calin et al., 2004a; Lu et al., 2005). As miRNA expression can also 
predict therapy outcome in haematological malignancies, miRNA profiling could advance to a 
novel prognostic tool (Calin et al., 2005; Garzon et al., 2008; Zhang et al., 2009). 
 
1.3.4 MicroRNAs and the NOTCH pathway 
An interaction between miRNA expression and the NOTCH pathway was expected, given 
the widespread regulation of multiple biological processes by both. The first indication for a 
possible interplay between miRNAs and the NOTCH pathway was described by Stark et al. who 
identified NOTCH target genes (Enhancer of split (E(spl), Bearded (Brd) complex genes) regulated 
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by miR-7, miR-4, miR-79, miR-2 and miR-11 in Drosophila (Lai et al., 2005; Stark et al., 2003). 
Another miRNA in Drosophila, miR-1, regulates the NOTCH pathway by targeting Delta, a NOTCH 
ligand, and thereby affecting cardiac differentiation (Kwon et al., 2005). Vice versa, NOTCH was 
shown to activate transcription of miR-61, a miRNA specific in C.elegans. miR-61 in turn inhibits the 
expression of VAV-1, a negative regulator of NOTCH. This positive feedback loop promotes vulval 
precursor cells in C.elegans to adopt a secondary fate (Yoo and Greenwald, 2005). An additional 
miRNA targeted by NOTCH in C.elegans is let-7a, which was also shown to be positively regulated 
in human 293T cells (Solomon et al., 2008). In a mouse myoblast cell line, it was reported that 
miR-146a regulates muscle cell differentiation by inhibiting expression of Numb, a NOTCH 
inhibitor (Kuang et al., 2009). Cross-talks have also been identified in cancer. miR-34 targets 
NOTCH1 in many cancer cell types (e.g. glioma cells, pancreatic cancer cells), thereby inhibiting 
cell growth and inducing apoptosis (Ji et al., 2008; Ji et al., 2009; Li et al., 2009; Pang et al., 2010). 
Another miRNA involved in regulating NOTCH signalling in tumour development is miR-199b-5p, 
which targets HES-1 in medulloblastoma (MB) tumours causing a decrease in cell growth (Garzia 
et al., 2009) (Table 1.2).  
 
miRNA 
Member of 
NOTCH pathway 
Interaction Model Model 
miR-7 
E(spl) complex 
genes                        
Brd complex genes*                
miRNAs negatively 
regulating E(spl) and Brd 
complex gene expression 
D.melanogaster 
Stark et al., 2003 
miR-4 
 
miR-79 
Lai et al., 2005 miR-2 
miR-11 
miR-1 Delta 
miR-1 negatively 
regulating Delta 
expression 
D.melanogaster Kwon et al., 2005 
miR-199-5p HES1 
miR-199-5p negatively 
regulating HES-1 
expression 
medulloblastoma Garzia et al., 2009 
miR-61 NOTCH 
NOTCH activating miR-61 
expression 
C.elegans 
Yoo and Greenwald, 
2005 
let-7a NOTCH 
NOTCH positively 
regulating miR-61 
expression 
C.elegans 
Solomon et al., 2008 
293T cells 
miR-34 NOTCH 
miR-34 negatively 
regulating NOTCH 
expression 
glioma cells  
Ji et al., 2008 
Ji et al., 2009 
pancreatic 
cancer cells 
Li et al., 2009 
Pang et al., 2010 
miR-146a NUMB 
miR-146a negatively 
regulating NUMB 
expression 
mouse myoblast 
cells 
Kuang et al., 2009 
 
Table 1.2 Interaction between miRNAs and members of the NOTCH pathway 
  *Enhancer of split (E(spl)); Bearded (Brd) 
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1.4 Molecular markers in paediatric T-ALL 
Although overall treatment outcome of children with T-ALL has improved dramatically 
over the years due to intensified treatment, a small number of patients develop recurrent disease 
and then respond poorly to the administered treatment. Molecular markers would therefore be 
of substantial value to identify high risk patients. In addition, good responders could benefit from 
therapy reduction, in order to avoid treatment-related toxicity and late complications. 
A risk stratification using commonly used clinical and laboratory prognostic markers like age, 
WBC, hyperdiploidy, presence of translocations, has not been shown to be useful because of their 
low predictive value (Goldberg et al., 2003; Pullen et al., 1999). In many study groups, risk 
assessment is based on early drug response and minimal residual disease (MRD) measurements 
(Cave et al., 1998; Conter et al., 2010). With the discovery of chromosomal translocations and 
aberrant expression of oncogenes, the search for new risk markers continues. Ferrando et al. 
firstly demonstrated the possible use of gene expression profiles in stratifying T-ALL patients 
according to risk. As epigenetic profiles in cancer differ from those in healthy tissues, epigenetic 
profiling showed to be potentially useful for risk prediction in other tumour types (Miyamoto and 
Ushijima, 2005). In T-ALL, specific DNA methylation profiles associate with good prognosis 
(Roman-Gomez et al., 2005). Other genomic imbalances in T-ALL, identified by genomic profiling, 
promise to be useful for early prognosis (Burkhardt et al., 2008; Remke et al., 2009). Recently, the 
frequency of NOTCH1 and FBXW7 mutations has become interesting for their application in risk 
prediction. In the ALL-BFM 2000 study group the presence of NOTCH1 mutations correlated with 
excellent long-term outcome (Breit et al., 2006). This result was confirmed by some studies 
(Asnafi et al., 2009; Malyukova et al., 2007; Park et al., 2009), but contradicted by others (Baldus 
et al., 2009; Larson Gedman et al., 2009; Mansour et al., 2009; van Grotel et al., 2008; Zhu et al., 
2006). 
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1.5 Aim of the present study 
The aim of this study was to analyse important pathways in the pathogenesis of T-ALL. A 
fundamental mechanism in leukaemogenesis is the aberrant up-regulation of the NOTCH1 
pathway. Understanding the underlying mechanisms and the accompanying effects of NOTCH1 
signalling in T-ALL could have fundamental implications for T-ALL therapies. 
In the first part of this study, the clinical potential of the activated NOTCH pathway was 
determined to develop diagnostic and treatment strategies. Specifically, the predictive value of 
NOTCH1 and FBXW7 mutations on the prognosis of paediatric T-ALL patients was characterised. 
The analysis was performed in a T-ALL patient cohort at first presentation and in patients with a 
relapse.  
Further, the regulation of miRNAs by the NOTCH1 pathway was investigated in paediatric T-ALL. 
MiRNAs acting as oncogenes or tumour suppressors in several types of cancer could be potential 
players in T-ALL malignancy. To address the question of a possible role of miRNAs in T-ALL, a cell-
based assay was set up in which miRNA expression was monitored upon NOTCH1 knockdown. 
Moreover, miRNA expression profiles from paediatric T-ALL patients were examined depending 
on the NOTCH1 mutational status. In addition, the miRNA signatures were tested for their 
prognostic usefulness. 
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2. Experimental procedures 
2.1 Materials 
2.1.1 Frequently used reagents and chemicals 
Glycine, Tris-(hydroxymethyl)-methylamine (Tris), sodium chloride (NaCl), methanol, 
ethanol, isopropanol and sodium dodecyl sulphate (SDS) were from Carl Roth GMBH (Karlsruhe, 
Germany). Dulbecco’s Modified Eagle Medium (DMEM), Roswell Park Memorial Institute-1640 
(RPMI-1640), Opti-MEM®, fetal bovine serum (FBS), non-essential amino acids (NEAA), sodium 
pyruvate and penicillin/streptomycin (Pen/Strep) were all from Gibco BRL div. of Invitrogen 
(Karlsruhe, Germany). Hexadimethrine bromide (Polybrene), diethylaminoethyl (DEAE)-dextran, 
paraformaldehyde (PFA) and chlorophorm were obtained from Sigma-Aldrich GmbH 
(Taufkirchen, Germany). Bacto™ Agar, Bacto™ Yeast Extract, Bacto™ Tryptone, cell strainers and 
FACS tubes were from BD Biosciences (Franklin Lakes, NJ, US).  Cell culture multi-well plates, 
dishes, flasks and falcons were obtained from Sarstedt (Nümbrecht, Germany). PVDF membranes 
were from GE Healthcare (Little Chalfont, UK), PBS from PAA laboratories (Pasching, Austria), 
ABsolute™ QPCR SYBR® Green Capillary mix from Thermo Scientific Inc. (Waltham, MA, US), 
TransIT®-LT1 Transfection Reagent from Mirus Bio (Madison, WI, US), Cryovials from Nunc (div. of 
Thermo Fisher Scientific Inc., Waltham, MA, US), Steriflip-HV Filter from Millipore (Billerica, MA, 
US), ultracentrifuge tubes from Beckman Coulter (Brea, CA, US), QIAzol Lysis Reagent from 
Qiagen (Hilden, Germany), Biocoll separating solution from Biochrom AG (Berlin, Germany) and 
TRIzol® from Invitrogen (Karlsruhe, Germany). 
 
2.1.2 Enzymes  
The restriction enzymes were obtained from New England Biolabs (NEB) (Ipswich, MA, 
USA) and were used according to the NEB guidelines. The reverse transcriptase, RevertAid™ H 
Minus M-MuLV, was from MBI Fermentas (Burlington, Ontario, Canada). PCR reactions were 
performed with Taq Polymerase or with HiFi Taq Polymerase (Roche). 
 
2.1.3 Buffers, Solutions and Media 
All buffers and solutions used in this study are listed in table 2.1.  
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Buffers and Solutions Preparation 
    
Antibiotic solutions (1000x) 100 mg/ml ampicillin in H2O 
  50 mg/ml kanamycin in H2O 
    
40 mM 6-amino-4-hexanoic acid 0.01% (w/v) SDS 
  pH 9.4 
    
DNA loading buffer (6x) 0.9% (w/v) bromophenol blue 
  60% (v/v) glycerol 
  60 mM EDTA pH 8.0 
    
Luria-Bertani (LB) agar (autoclaved) 15 g/l Bacto™ Agar in LB broth 
    
LB broth (autoclaved) 10 g/l Bacto™ Tryptone 
  5 g/l Bacto™ Yeast extract 
  5 g/l NaCl 
  pH 7.6 (adjusted with 5 N NaOH) 
    
TBE (10x) 0.89 M Tris base, pH 8.3 
  0.89 M boric acid 
    
Paraformaldehyde (PFA) 1% 1 g PFA 
  up to 100ml PBS 
  filter-sterilise 
    
Growth medium (T cell line) 10% FBS 
  1% Penicillin/Streptomycin 
  in RPMI 
    
Growth medium (293FT) 10% FBS 
  1% Penicillin/Streptomycin 
  1x Non essential amino acids 
  1% Sodium Pyruvate 
  in DMEM 
    
Diethylaminoethyl-Dextran 5 mg DEAE-Dextran 
(DEAE-Dextran) 5 mg/ml up to 1 ml PBS 
  filter-sterilise 
    
Hexadimethrine bromide (Polybrene) 6 mg  Polybrene 
6 mg/ml up to 1 ml H2O 
 
filter-sterilise 
 
  
 
Table 2.1 List of buffers and solutions 
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2.1.4  Kits 
Listed below in table 2.2 are the kits that were used in this work. Unless stated otherwise, 
the manufacturer’s recommendations were followed. 
Application Name Supplier 
Plasmid DNA extraction from 
agarose gels 
NucleoBond Xtra Midi® , 
NucleoSpin Plasmid ® 
Macherey-Nagel, Düren, Germany 
PCR clean-up NucleoSpin Extract II ® Macherey-Nagel, Düren, Germany 
DNA preparation from E.coli NucleoSpin Extract II ® Macherey-Nagel, Düren, Germany 
RNA extraction miRNeasy ® Qiagen, Hilden, Germany 
genomic DNA extraction QIAamp ® Qiagen, Hilden, Germany 
Table 2.2 List of kits 
 
2.1.5 Plasmids 
A description of the plasmids used and their respective sources are documented in table 
2.3. Plasmids that were kindly provided by other laboratories are indicated as such. The integrity 
of all DNA constructs employed in the experimental studies was verified by forward and reverse 
DNA sequencing (GATC biotech AG, Konstanz, Germany).  
Plasmid Name Template Insert Fluorophore Source 
MISSION® Control Vector 
pLKO.1-puro CMV-TurboGFP™  
pLKO.1-
puro 
- Turbo-GFP™  Sigma-Aldrich 
MISSION® Non-Target 
shRNA Control Vector 
pLKO.1-
puro 
Non-Target shRNA - Sigma-Aldrich 
MISSION® pLKO.1-puro-
NOTCH1 shRNA1 
pLKO.1-
puro 
NOTCH1 shRNA - Sigma-Aldrich 
MISSION® pLKO.1-puro-
NOTCH1 shRNA2 
pLKO.1-
puro 
NOTCH1 shRNA - Sigma-Aldrich 
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MISSION® pLKO.1-puro-
NOTCH1 shRNA3 
pLKO.1-
puro 
NOTCH1 shRNA - Sigma-Aldrich 
MISSION® pLKO.1-puro-
NOTCH1 shRNA4 
pLKO.1-
puro 
NOTCH1 shRNA - Sigma-Aldrich 
MISSION® pLKO.1-puro-
NOTCH1 shRNA5 
pLKO.1-
puro 
NOTCH1 shRNA - Sigma-Aldrich 
pMD2.G   VSVG - 
Dr Violaine 
Rosenstiel-Goidts 
(DKFZ) 
psPAX2   gag, rev, pol - 
Dr Violaine 
Rosenstiel-Goidts 
(DKFZ) 
 
Table 2.3 List of plasmids  
 
2.1.6 Oligonucleotides 
All primers were purchased from Sigma-Aldrich (Taufkirchen, Germany) or biomers.net 
(Ulm, Germany). PCR primers were obtained in desalted, lyophilized form, and were diluted in 
H2O. All primers used in this work are listed in table 2.4. 
Sequencing of genes (see 2.2.2.1) 
Genes FW 5'-3' RV 5'-3' 
NOTCH1 HD-N agccccctgtacgaccagta gagggcccaggagagttg 
NOTCH1 HD-C gtggcgtcatgggcctca tagcaactggcacaaacagc 
NOTCH1 TAD agactggcccacctcgtctct gctctccactcaggaagctc 
NOTCH1 PEST aaacatccagcagcagcaaa aaaggaagccggggtctc 
FBXW7 exon9 ccaggccagagctatcataac agacaaaacgctatggctttcc 
FBXW7 exon10 aaccttgactaaatctaccatgtt ctggatcagcaatttgacagtg 
 
 
 
 
 
 
 
 
Experimental procedures 
 
26 
Sequencing of plasmids (see 2.2.2.1) 
Plasmid FW 5'-3' RV 5'-3' 
pLKO.1-puro ggactatcatatgcttaccgt tctttcccctgcactgtacc 
   
quantitative PCR (see 2.2.1.10.1) 
mRNA/miRNA FW 5'-3' RV 5'-3' 
ACTG1 tacagcttcaccaccacggc tacccaggaaggaaggctgg 
NOTCH1 tgcactgcgaggtcaacac caggcacttggcaccattc 
HES1 aacacgacaccggataaacc cgagtgcgcacctcggta 
primary ACTG1 tttccccagtcattttctgc gccagtgtgatgtgtggaga 
pri-miR-17~92 gtggggattgtgaccagaag gcaaccccaaaagtgaaatg 
pri-miR-491 gtggggaatggggaattaag gtgctaacatcgagcagtgg 
   
miQPCR (see 2.2.1.10.2) 
mature miRNA FW 5'-3' RV 5'-3' 
hsa-miR-106a aaaagtgcttacagtgcaggtagg linker primer (patented) 
hsa-miR-106b taaagtgctgacagtgcagatgg linker primer (patented) 
hsa-miR-15a gcagcacataatggtttgtgg linker primer (patented) 
hsa-miR-16 tagcacgtaaatattggcgg linker primer (patented) 
hsa-miR-17 caaagtgcttacagtgcaggtagg linker primer (patented) 
hsa-miR-181a caacgctgtcggtgagtg linker primer (patented) 
hsa-miR-181b cattgctgtcggtgggtg linker primer (patented) 
hsa-miR-181c cattcaacctgtcggtgagtg linker primer (patented) 
hsa-miR-181d acattgttgtcggtgggtg linker primer (patented) 
hsa-miR-18a taaggtgcatctagtgcagataggg linker primer (patented) 
hsa-miR-18b taaggtgcatctagtgcagttagg linker primer (patented) 
hsa-miR-19a tgtgcaaatctatgcaaaactgag linker primer (patented) 
hsa-miR-20a taaagtgcttatagtgcaggtaggg linker primer (patented) 
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hsa-miR-20b caaagtgctcatagtgcaggtagg linker primer (patented) 
hsa-miR-223 tgtcagttgtcaaataccccagg linker primer (patented) 
hsa-miR-25 tgcacttgtctcggtctgag linker primer (patented) 
hsa-miR-363 aattgcacggtatccatctgtagg linker primer (patented) 
hsa-miR-491-3p cttatgcaagattcccttctacgg linker primer (patented) 
hsa-miR-92a cttgtcccggcctgtg linker primer (patented) 
hsa-miR-92b cccggcctccgg linker primer (patented) 
hsa-miR-93 gtgctgttcgtgcaggtagg linker primer (patented) 
RNU6 gcttcggcagcacatatactaa linker primer (patented) 
 
Table 2.4 List of oligonucleotides  
 
2.1.7 Bacterial strains 
For propagation of vectors, the heat shock competent E.coli strain, XL1 blue, (La Jolla, CA, 
USA) was used. The genotype of this strain is the following: hsdR17, supE44, recA1, endA1, 
gyrA96, thi, relA1, lac/F´[proAB+ lacIa, lacZΔM15:Tn10(TetR)]. 
 
2.1.8  Cell lines 
The virus producer cell line 293FT was obtained from Invitrogen. Cells were cultured in 
flasks at 37°C, 5% CO2 in Dulbecco’s minimal essential medium (DMEM), supplemented with 10% 
foetal bovine serum (FBS), 1% antibiotics (penicillin/streptomycin), 1x non-essential amino acids 
(NEAA) and 1% Sodium Pyruvate.  
The T cell line (CCRF-CEM) was purchased from DMSZ (Braunschweig, Germany). Cells were 
cultured in flasks at 37°C, 5% CO2 in Roswell Park Memorial Institute-1640 (RPMI-1640), 
supplemented with 10% foetal bovine serum (FBS) and 1% antibiotics (penicillin/streptomycin). 
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2.2 Methodologies 
2.2.1 Molecular Biology 
2.2.1.1  Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) was used to selectively amplify particular DNA segments 
for the mutation sequencing screen. The reaction mixture was typically for a final volume of 50 µl 
consisting of: DNA polymerase buffer, 1.5 mM MgCl2, 5% DMSO, 0.2 µM of each primer (sense and 
anti-sense), 0.2 mM dNTP, 2 units of DNA polymerase and 50 ng of template DNA in dH2O. This 
PCR mixture was used to amplify plasmids, exons 27 (HD-N) and 34 (PEST domain) of NOTCH1 and 
exons 9 and 10 of FBXW7. For PCR amplification exons 28 (HD-C) and 34 (TAD domain) of NOTCH1, 
betaine 5 M was added in addition to the previous mixture.   
A typical temperature program was as follows: 
10’ 95°C denaturation  1 cycle 
30’’ 95°C denaturation   
30’’ 57°C annealing  40 cycles 
1’ 72°C elongation 
10’ 72°C final extension  1 cycle 
The PCR products were separated using gel electrophoresis to estimate the quality and the 
quantity. For DNA sequencing, PCR products were sent to GATC biotech AG, Konstanz, Germany. 
 
2.2.1.2  Transformation of bacteria 
Fifty nanograms of plasmid DNA were mixed with 100 μl of the transformation-competent 
E.coli strain, XL1 blue, incubated on ice for 30 min. The cells are heat-shocked for 90 s at 42°C on 
ice and subsequently incubated on ice for 3 min. 600 μl of LB medium was added and the mixture 
was incubated for 1h at 37°C. The transformed bacteria were then spread on LB agar plates 
containing the appropriate antibiotic and incubated overnight at 37°C. 
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2.2.1.3  Bacterial culture and isolation of plasmid DNA 
Single bacterial clones were incubated in 200 ml LB medium containing the appropriate 
antibiotic in the shaker, overnight at 37°C. Cells were pelleted by centrifugation at 4500 g for 15 
min, 4°C in a 5415R centrifuge (Eppendorf). To prepare large amounts of plasmid DNA, the 
NucleoBond Xtra Midi® kit was used according to the manufacturer’s instructions. Lentiviral 
vectors were treated as low copy-number plasmids. 
 
2.2.1.4  Ficoll-Hypaque density gradient centrifugation 
Fresh blood samples were collected at the “blood bank”, INF 305, Heidelberg, Germany. 
The samples were diluted with an equal volume of 1x PBS and mixed by inversion. This mix was 
overlaid slowly with an equal volume of Ficoll reagent in a 50 ml Falcon tube and subsequently 
centrifuged without brake at 800 g for 20 min at room temperature in a 5810R centrifuge from 
Eppendorf. The interphase (white cell layer containing the lymphocytes) wass carefully 
transferred into a fresh 50ml Falcon tube. 30 ml of 1x PBS were added, mixed by inversion and 
centrifuged at 500 g for 10 min. The supernatant was discarded and the cell pellet was washed in 
20 ml 1x PBS. The cells were centrifuged at 500 g for 5 min. The remaining cell pellet was 
resuspended in 2 ml 1x PBS to determine the cell number. The cells were collected once more by 
centrifugation at 500 g for 5 min, and resuspended in TRIzol® reagent. Resuspended cells in 
TRIzol® were stored at -20°C or total RNA was extracted directly from these samples.  
 
2.2.1.5  Genomic DNA extraction 
To extract genomic DNA, the QIAamp® kit (Qiagen) was used according to the 
manufacturer’s instructions. 
 
2.2.1.6  Determination of DNA concentration and quality 
DNA concentration was determined using the Biophotometer®, Eppendorf (Hamburg, 
Germany). Sequencing of all DNA constructs and all PCR products was performed to confirm the 
sequences by GATC Biotech AG (Konstanz, Germany). Sequence analysis was performed by 
Chromas Lite (Technelysium Pty Ltd) or Mutation Surveyor™ (Softgenetics, US). 
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2.2.1.7  DNA agarose gels 
 
DNA samples mixed with DNA loading buffer were loaded on 1% agarose (w/v) gels 
containing ethidium bromide (EtBr). 250 ng of a 100 bp or a 1 kb DNA ladder used as a size marker 
allowed the estimation of the size of DNA fragments. Agarose gels were usually run at 120V, and 
visualised using a UV transilluminator (Herolab UVT-28 ME). 
 
2.2.1.8  Total RNA extraction 
Two RNA extraction methods were used in this study. For both methods, cells were lysed 
in QIAzol Lysis Reagent and stored at -20°C until RNA extraction. In the first protocol (named 
miRNeasy protocol), the miRNeasy Mini® kit was used according to the manufacturer’s 
instructions. To prepare total RNA using the second method (named TRIzol® method), 
chloroform is added (1/5 of TRIzol® volume) to the tube, and shaken for 15 sec. After 3 min of 
incubation at room temperature, the mix is centrifuged at 12000 g for 15 min at 4°C. Three 
different phases were formed. The upper aqueous phase was carefully transferred into a fresh 
tube. For RNA precipitation, isopropanol was then added (1/2 volumes of TRIzol® volume) and the 
mix centrifuged at 12000 g for 15 min at 4°C. The pellet formed was washed using 1 ml of ethanol 
75% and spun again for 10 min (12000 g; 4°C). The supernatant was discarded completely, and the 
pellet was resuspended in H2Obidest by incubating the tubes for 5 min at 50°C. 
 
2.2.1.9  Determination of RNA concentration and quality 
RNA concentration was measured using the Biophotometer®, Eppendorf (Hamburg, 
Germany). To check the RNA quality, 1 µl of sample was run on the 2100 Bioanalyzer using the 
RNA Nano 6000 kit (Agilent, Santa Clara, US) according to the manufacturer’s instructions. 
 
2.2.1.10  cDNA synthesis and quantitative PCR 
2.2.1.10.1  Quantitative PCR for mRNA 
For quantitative PCR (qPCR), 1 µg of total RNA was used for reverse transcription (RT). 
The RNA and 1 µl of random primers (0.2 µg/µl) were denatured at 70°C for 10min, and cooled 
down on ice for 2min. The reverse transcription reaction mixture contained a total volume of 25 µl 
consisting of RT buffer, 0.4 mM dNTPs, 200 units of RevertAid H Minus M-MuLV Reverse 
Experimental procedures 
 
31 
Transcriptase, 1 µl random primers (0.2 µg/µl) and 1 µg of denatured total RNA. The mix was 
incubated at 42°C for 90 min, then at 70°C for 10min for stopping the reaction. After cDNA clean-
up using the NucleoSpin Extract II ®, the cDNA was eluted in 50 µl H2O. For quantitative PCR 
(qPCR), the reaction mix (20 µl) contained ABsolute™ QPCR SYBR® Green Capillary mix, 0.4 µM of 
the forward and reverse primers and 2 µl of cDNA. The qPCR mixture was run on a StepOnePlus™ 
from Applied Biosystems (ABI) according to the following thermocycle protocol: 
 
10’10’’ 95°C denaturation  1 cycle 
3’’ 95°C denaturation   
10’’ 60°C annealing   40 cycles 
20’’ 72°C extension  
15’ 95°C final extension  1 cycle 
1’ 60°C     1 cycle 
60°C to 95°C dissociation step 
Threshold cycles (Ct) were defined as the fractional cycle number at which the fluorescence 
passed the fixed threshold. Ct values were extracted by using the 7500 software v2.0.1 (ABI) and 
calculations for normalisation and analysis were done in Excel (Microsoft Office). 
 
2.2.1.10.2  miQPCR  
For miQPCR (patent application EP 09 002 587.5), total RNA was first dephosphorylated 
for 30 min at 37°C, followed by 5 min at 90°C. The reaction mixture for a final volume of 3.5 µl 
contained 500ng of total RNA, 10 U calf intestinal phosphatase (CIP; Ambion) and CIP buffer.  
Total RNA was then tailed to a linker adaptor by mixing the dephosphorylated RNA with NEB 
buffer, 17% PEG, 2.4mM ATP, 20 U RNase Inhibitor (NEB), 40 U T4 RNA ligase (NEB) and 5 µM RNA 
linker in a total volume of 15 µl. The mix was incubated for 120 min at 37°C, followed by 5 min 
incubation at 85°C. To reverse transcribe (RT) the RNA, the mix was incubated with 10 mM dNTP 
and 100 µM of Upm3 primer (total volume 22 µl) for 3 min at 80°C, then cooled down on ice for 5 
min. A mix of 7 µl, containing RT buffer and 0.1M DTT, was added, and incubated at 48°C for 3 min. 
The cDNA synthesis was completed by incubating the reaction mix with 200 U superscript II 
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(Invitrogen), for 60 min at 48°C. The reaction was stopped by incubating the mix for 10min at 
70°C. 1 µl of RNase H (NEB) was added, and incubated for 30 min at 37°C. The cDNA was then 
diluted with 215 µl of H2O. For each qPCR reaction, 5 ng of cDNA were used. cDNAs were 
amplified by using 0.5 µM of miRNA- and linker- specific primers and SYBR Green (Applied 
Biosystems (ABI)). The mixture was run on a ABI 7500 instrument. The amplification protocol was 
as follows: 
2’ 50°C      1 cycle 
10’ 95°C denaturation   1 cycle 
15’’ 95°C denaturation   50 cycles 
1’ 60°C  annealing and extension 
60°C to 95°C  dissociation step  1 cycle 
Threshold cycles (Ct) were defined as the fractional cycle number at which the fluorescence 
passed the fixed threshold. Ct values were extracted by using the 7500 software v2.0.1 (ABI) and 
calculations for normalization and analysis were done in Excel (Microsoft Office). 
 
2.2.2  Cell culture 
2.2.2.1  Freezing and thawing cell lines 
Confluent 293FT and CCRF-CEM cells were washed in PBS and detached briefly with 1ml 
trypsin/EDTA. After adding 10 ml of medium, cells were centrifuged at 120 g for 4 min. The cell 
pellet was washed in 10 ml PBS, and centrifuged at 120 g for 4 min. The pellet was carefully 
resuspended in 1 ml DMEM (293FT), or RPMI-1640 (CCRF-CEM), containing 10% DMSO. The cell 
suspension was transferred into a cryovial and frozen at -80°C overnight. The vial was then 
transferred to a liquid nitrogen tank for storage. For thawing cells, a frozen vial was immediately 
transferred from liquid nitrogen into a water bath at 37°C until completely thawed. The cells were 
subsequently transferred into a 50ml falcon containing 10ml fresh medium, and centrifuged at 120 
g for 4min. The cell pellet was taken up in medium and transferred into a 75cm2 flask. 24h after 
thawing, the medium was replaced to remove all traces of DMSO. 
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2.2.2.2  Lentiviral production 
The 293FT cell line was cultured in growth medium in 175cm2 flasks to a 50-70% confluence. 
Transfection of DNA constructs was carried out using TransIT®-LT1 Transfection Reagent. 100 µl of 
TransIT®-LT1 Reagent was diluted in 6 ml of Opti-MEM® and incubated for 10 min at room 
temperature. A mixture of 20 µg psPAX2, 10 µg pMD2.G and 20 µg of a lentiviral construct 
(pLKO.1-puro) was added to the diluted TransIT-LT1 Reagent, mixed gently by inversion and 
incubated for 20 min at room temperature while the growth medium was changed to 20 ml fresh 
growth medium. The TransIT-LT1 Reagent-DNA complex was added dropwise to the cells and the 
flask gently rocked back and forth. The transfected 293FT cells were incubated 48h at 37°C, 5% 
CO2. Growth medium was harvested in 50 ml falcon tubes after 48h and centrifuged at 800 g for 5 
min. The supernatant was filtered using a 0.45 µm Steriflip-HV Filter (SE1M003M00, Millipore) and 
stored in a sealed bag at 4°C overnight. 25ml fresh growth medium was added to the cells which 
were incubated for another 24 hours at 37°C, 5%CO2. After 72h post-transfection, growth medium 
was harvested, centrifuged and the supernatant filtered. The filtered medium was transferred 
into Beckman ultracentrifuge tubes, and centrifuged for 2h, at 24ooo rpm at 4°C in a Beckman 
Optima L-70 ultra-speed centrifuge (rotor SW28). The supernatant was decanted and the viral 
particles taken up in approximately 200 µl PBS. The concentrated viral particles were distributed 
equally into 3 cryovials and stored at -80°C until further usage. 
 
2.2.2.3  Lentiviral titration 
105 of 293FT cells were plated overnight in 2 ml growth medium in each well of a 6-well 
plate. Growth medium was then replaced by 1 ml of fresh growth medium containing 6 µg/ml 
polybrene. 1 µl of concentrated viral particles was added to 1 well (1 ml). To achieve 10-fold serial 
dilutions of the viral particles, 100 µl of the diluted particles were added to the next well. The 
dilutions ranged from 10-3 to 10-7. 24h post-transduction the growth medium containing the viral 
particles was removed and replaced by fresh medium. 72h post-transduction cells were fixed in 
PFA 1% (see 2.2.2.5). Cells were taken up in 1 ml of PBS, passed through a 70 µm cell strainer and 
collected in FACS tubes. The titration was measured by BD FACScan™ Flowcytometer measuring 
GFP (BD Biosciences, Franklin Lakes, US) (see 2.2.2.6). 
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2.2.2.4  Lentiviral transduction 
For each lentiviral transduction, 2x105 CCRF-CEM cells were added to 1ml growth medium 
(RPMI, 10% foetal bovine serum (FBS), 1% antibiotic (penicillin/streptomycin)) containing 8µg/ml 
DEAE. Between 4x107 and 7x107 TU/µl (transducing units/µl; see 2.2.2.7) were added to the each 
well. A 30 min centrifugation at 200 g improved the binding of the virus to the surface of the cells. 
Cells were resuspended in the same medium, plated in 6-well plates and incubated for 24h at 37°C, 
5% CO2. At 24h post-transduction, the growth medium was replaced by 2ml fresh growth medium. 
At 72h, 120h and 168h post-transduction, the number of cells was counted for each transduction 
by using the Neubauer counting chamber. The GFP expressing (GFP+) cells were fixed (see 2.2.2.5) 
and scanned using the BD FACScan™ Flowcytometer (BD Biosciences, Franklin Lakes, US) to 
estimate the transduction efficiency (see 2.2.2.6). All other cells were suspended in QIAzol Lysis 
Reagent and stored at -20°C. 
 
2.2.2.5  Cell fixation 
Cells were washed in 1x PBS and trypsinized for 5 min. Cells taken up in 1x PBS were then 
collected by centrifugation at 200 g, 4 min and fixed in 100 µl PFA 1%. For fixation, cells were 
incubated 10min at room temperature. 1.5 ml of PBS was added and cells were centrifuged again 
at 200 g, 4min.  
 
2.2.2.6  Determination of transduction efficiency 
Cells expressing GFP were detected by the BD FACScan™ Flowcytometer (BD Biosciences, 
Franklin Lakes, US). To determine the number of GFP+ cells, the CellQuest™ software version 3.3 
from Becton Dickinson was used according to the manufacturer’s instructions.  
 
2.2.2.7  Calculating the lentiviral titre 
The transducing titre is expressed in transducing units (TU). To calculate TU, the following 
formula was used:  
    ⁄  
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where P = average (% GFP+ cells in dilution 10n; 10 x % GFP+ cells in dilution 10n-1); C = number of cells 
at time of transduction; V = µl of viral supernatant added (dilution 10n). 
To measure the percentage of GFP+ cells, the BD FACScan™ Flowcytometer was used. The 
CellQuest™ version 3.3 software from Becton Dickinson determined the percentage. From the 
dilutions ranging from 10-3 to 10-7, the 2 samples were used that contained a measurable number 
of GFP+ cells, but that were non-saturated (<95% of GFP+ cells). Lentiviral titres varied between 
2x105 and 5x105 TU/µl. 
 
2.2.3 MiRNA microarray analysis 
Sample preparation, hybridisation and chip scanning were done by Sabine Schmidt and 
Mirco Castoldi at EMBL. MiChip image analysis was done by loading the chip images into Genepix 
Pro version6.0 software (Axon Instruments) generating raw “gpr files”. 
The raw miRNA microarray files concerning the knock-down experiments were analysed using the 
MiChip package (http://www.bioconductor.org/packages/2.6/bioc/html/MiChip.html; by Jonathon 
Blake, EMBL) on the Bioconductor software. This package is based on a whole chip median 
normalisation and includes a set of functions for loading data from several MiChip hybridisations, 
flag correction, filtering and summarising the data. The normalised output files were loaded into 
Excel. The ratio was calculated of each experiment by dividing the NOTCH1 shRNA sample to the 
corresponding non-target shRNA (scramble) sample. For the 72h experiments, these ratios were 
then analysed for differential gene expression analysis by T-test (p<0.02 for both NOTCH1 shRNA 
experiments). The fold change was calculated by dividing the mean of the NOTCH1 shRNA 
samples by the mean of the scramble samples. From the generated list of candidate miRNAs were 
filtered out those that were not or lowly expressed. This list was further filtered by comparing if 
the same trend was observed also in the pool of experiments at 120h.  
The miRNA microarray data from the T-ALL patient samples were analysed using two 
normalisation methods. In Figures 4.6 and 4.7, the MiChip package was used. In Figure 4.8 a 
normalisation based on a linear model was employed by Wolfgang Huber (EMBL) and Julia 
Engelmann (Regensburg). 
For hierarchical clustering (HCL), the MiChip-normalised data was uploaded into TIGR MeV 4.0 
(MultiExperimentViewer; http://www.tm4.org; Wang et al., 2008).  
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2.2.4 Statistical analyses 
 Differences in the distribution of prednisone response and MRD kinetics measurements 
among patient subsets were analysed using the Fisher’s exact test. Estimated probability of 5-
years EFS (pEFS) and estimated cumulative incidence of relapse (pCIR) analyses (at first 
presentation) were done by Martin Zimmermann, Hanover. Estimated probability of 5-years EFS 
(pEFS) analyses (at relapse) were done by Jana Hof, Berlin. The pEFS curves include all events 
(relapse, second malignancy, death in continuous complete remission and death before complete 
remission).  
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3. Results 1: The role of NOTCH1 and FBXW7 mutations as molecular 
biomarkers in paediatric T-ALL 
In precursor B-cell lymphoblastic leukaemia some prognostic markers have been identified 
that are of clinical relevance (hyperdiploidy, hypodiploidy and specific translocations e.g. t(9;22)) 
(Fletcher et al., 1992; Martinez-Climent, 1997; Trueworthy et al., 1992). However, in paediatric T-
cell leukaemia such valuable markers are still missing. One of the purposes of this work is to study 
the possible use of NOTCH1 and FBXW7 mutations as prognostic biomarkers in paediatric T-ALL, 
both at initial presentation and at relapse.  
 
3.1 NOTCH1 and FBXW7 mutations in paediatric T-ALL at initial presentation 
It has been reported that 50% of children with T-ALL carry NOTCH1 activating mutations 
(Weng et al., 2004). The first report, in which the potential of NOTCH1 mutations was investigated, 
was undertaken in the context of the ALL-BFM 2000 study group (Breit et al., 2006). This study 
showed that children with NOTCH1 mutations showed an improved long-term outcome compared 
to those without NOTCH1 mutations. We now extended the study to 301 patients enrolled in the 
ALL-BFM 2000 study, the largest cohort of paediatric T-ALL samples analysed to date. 
 
3.1.1 Frequency of NOTCH1 and FBXW7 mutations in paediatric T-ALL at initial presentation 
Of 301 T-ALL patients, 30 (10%) carried mutations in both genes, FBXW7 and NOTCH1, 120 
(40%) harboured NOTCH1 mutations only, and 12 (4%) contained FBXW7 mutations only (Figure 3.1). 
All mutations were heterozygous. 
 
Figure 3.1 Frequency of NOTCH1 and FBXW7 mutations in childhood T-ALL at initial presentation 
30  
(10%) 
120  
(40%) 12  
(4%) 
139  
(46%) 
NOTCH1+FBXW7 mutated
NOTCH1 mutated
FBXW7 mutated
NOTCH1/FBXW7 non-
mutated
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In the 150 patients (50%) with NOTCH1 mutations, 94 children (31.2%) had a mutation in the 
heterodimerisation domain (HD), 29 (9.6%) in the TAD-PEST domain, and 27 (9 %) in both. All 
NOTCH1 mutations affecting these domains are hypothesised to result in an aberrant up-
regulation of NOTCH1 signalling (Weng et al., 2004).  
FBXW7 mutations, found in 42/301 patients (14%), were all located in exons 9 and 10, coding for the 
WD repeats 2 to 4 (Figure 1.5). The D domain in the N-terminal part of the protein is unaffected by 
the mutations and functions properly. By sequestering non-mutated FBXW7 proteins of the 
normal allele, the truncated FBXW7 is hypothesised to function as dominant-negative. The 
frequency of mutations is similar to results published by other study groups (Baldus et al., 2009; 
Malyukova et al., 2007; Weng et al., 2004). 
 
3.1.2 NOTCH1 mutations correlate with improved early treatment response and a better long-
term outcome 
Patients were grouped according to their NOTCH1 mutational status, and were compared 
in relation to their early treatment response (assessed by prednisone response on day 8 and MRD 
kinetics on days 33 and 78). Prednisone good response (PGR) was measured in 102/149 patients 
(68%) with NOTCH1 mutations, but only in 73/145 (50%) patients without NOTCH1 mutations 
(p=0.002) (table 3.1).  
MRD measurements on day 33 were available for 267 patients (138 NOTCH1 mutated, 129 NOTCH1 
non-mutated) and for 274 patients on day 78 (140 NOTCH1 mutated and 134 NOTCH1 non-mutated). 
47/138 (34%) NOTCH1 mutated patients and 23/129 (18%) NOTCH1 non-mutated patients showed a 
favourable response on day 33 (p=0.003). On day 78, 103/140 (74%) of the NOTCH1 mutated 
patients showed a favourable response compared to only 58/134 (43%) patients without NOTCH1 
mutations (p<0.0001).  
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Prednisone Response (Day 8) * 
  PPR (%) PGR (%) Data not available P‡ 
NOTCH1 mutated 47 (32) 102 (68) 1 p=0.002 
NOTCH1 non-mutated 72 (50) 73 (50) 6   
          
MRD (Day 33) † 
  Unfavourable (%) Favourable (%) Data not available P‡ 
NOTCH1 mutated 91 (66) 47 (34) 12 p= 0.003 
NOTCH1 non-mutated 106 (82) 23 (18) 22   
          
MRD (Day 78) † 
  Unfavourable (%) Favourable (%) Data not available P‡ 
NOTCH1 mutated 37 (26) 103 (74) 10 p<0.0001 
NOTCH1 non-mutated 76 (57) 58 (43) 17   
 
 
Table 3.1 NOTCH1 mutations associate with favourable early treatment response in paediatric T-
ALL.  
* PPR: ≥1000 leukaemic blood blasts/μL on treatment day 8; PGR: <1000/μL.  
† Unfavourable MRD: ≥10-4; Favourable MRD: <10-4.  
‡ P-value; Fisher’s Test.  
 
Similar results were obtained for long-term outcome with a pEFS of 87% in the NOTCH1 mutated 
groups, but only 74% in the non-mutated group (p=0.005; Figure 3.2A). Moreover, a difference in 
the relapse rate was observed, being of 7% in the mutated group, and of 17% in the non-mutated 
group (p=0.007; Figure 3.2B). In summary, the present analysis of a large group of patients 
confirms that activating NOTCH1 mutations correlate strongly with improved early treatment 
response and with excellent long-term outcome.  
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Figure 3.2 NOTCH1 mutations correlate with excellent long-term outcome in T-ALL.  
(A) Kaplan-Meier estimate of the probability of event-free survival (pEFS) in NOTCH1 
mutated and NOTCH1 non-mutated patients. (B) Cumulative incidence of relapse (pCIR) in 
NOTCH1 mutated and NOTCH1 non-mutated patients 
 
 
In addition, initial CNS involvement was analysed in the total cohort of T-ALL patients. Clinical data 
on the presence of initial CNS involvement were available in 254 patients. Twelve out of 127 (9%) 
patients with NOTCH1 mutations showed initial CNS involvement compared to 18/127 (12%) in the 
NOTCH1 non-mutated group. The incidence of relapses with CNS involvement was also similar 
between NOTCH1 mutated and non-mutated patients, both in the entire group (pCIR 2%1% vs 
4%2%), and in the high risk subgroup of patients (pCIR 3%3% vs 5%3%). Overall, the rate of CNS-
involved relapses was low. 
 
3.1.3 The favourable effect of NOTCH1 mutations is restricted to the standard and 
intermediate risk groups  
The next aim was to analyse the effect of NOTCH1 mutations on pEFS and relapse in the 
different risk groups. These groups are defined in the ALL-BFM 2000 protocol by the in vivo early 
treatment response of the patients. The standard risk patients (SR) show a PGR and negative 
MRD measurements on days 33 and 78. The high risk group (HR) is defined by a PPR, a MRD 
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response ≥10-3 on day 78, or both. All remaining patients are stratified into the intermediate risk 
group (MR).  
The SR/MR groups encompassed 168 patients. The NOTCH1 mutated patients showed an excellent 
pEFS of 95% compared to only 83% in the NOTCH1 non-mutated patients (p=0.02; Figure 3.3A). A 
trend towards a lower relapse rate in the NOTCH1 mutated group (pCIR 0.04), compared to the 
NOTCH1 non-mutated patients (pCIR 0.11), was observed (p=0.11; Figure 3.3B). Interestingly, no 
significant difference in pEFS could be observed in the HR group between NOTCH1 mutated (72%) 
and non-mutated patients (66%; p=0.49; Figure 3.3C). Although non-significant, a trend towards a 
lower relapse rate in the NOTCH1 mutated group (pCIR 0.12) was observed, compared to the 
NOTCH1 non-mutated group (pCIR 0.23; p=0.13; Figure 3.3D). In contrast, the rate of non-relapse 
events is slightly higher in the NOTCH1 mutated group (8/51) than in the non-mutated group (9/82; 
Table 3.2). 
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Figure 3.3 The favourable effect of NOTCH1 mutations on long-term outcome is restricted to the 
standard and intermediate risk groups.  
(A) Kaplan-Meier estimate of the probability of event-free survival (pEFS) in NOTCH1 
mutated and NOTCH1 non-mutated SR/MR patients. (B) Cumulative incidence of relapse 
(pCIR) in NOTCH1 mutated and NOTCH1 non-mutated SR/MR patients. (C) Kaplan-Meier 
estimate of the probability of event-free survival (pEFS) in NOTCH1 mutated and NOTCH1 
non-mutated HR patients. (D) Cumulative incidence of relapse (pCIR) in NOTCH1 mutated 
and NOTCH1 non-mutated HR patients. 
 
In conclusion, the favourable effect of NOTCH1 mutations on long-term survival is restricted to 
patients characterised already by a good response to treatment protocol of the ALL-BFM 2000. 
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  SR/MR HR 
  
 
NOTCH1 
mutated 
NOTCH1 non-
mutated 
NOTCH1 
mutated 
NOTCH1 non-
mutated 
Non-relapse Event 2 5 8 9 
 
Death in CCR* 0 1 7 8 
 
Death before CR†  0 3 1 0 
 
Second malignancy 2 1 0 1 
Relapse 4 7 6 18 
All Events 6 12 14 27 
 
Table 3.2 List of relapse and non-relapse events in the SR/MR and HR groups 
* Death in CCR (continuous complete remission) 
  † Death before CR (complete remission) 
 
 
3.1.4 FBXW7 inactivating mutations correlate with early treatment response but do not 
predict favourable late treatment response or better long-term outcome 
Previously, inactivating FBXW7 mutations have been identified in paediatric T-ALL, 
although in a lower frequency than NOTCH1 mutations. The FBXW7 mutations are mainly found in 
the WD40 repeats which mediate substrate recognition. In patients with FBXW7 mutations, it is 
hypothesised that NOTCH1, as a FBXW7 target, is not degraded, so that NOTCH1 signalling 
remains active. Therefore, it is plausible that these patients have similar clinical characteristics and 
that both types of mutations synergise to sensitise leukaemia cells for treatment. 
Prednisone response was available for all the patients with FBXW7 mutations and in 252/259 
patients without FBXW7 mutations. PGR was observed in 37/42 patients (88%) in the FBXW7 
mutated group compared to 138/252 (55%) in the non-mutated group (p=0.0003; Table 3.3). 
Sixteen out of 39 FBXW7 mutated patients showed a favourable MRD response on day 33 
compared to 174/228 in the non-mutated group (p=0.03; Table 3.3). On day 78, however, only a 
non-significant trend could be observed; favourable MRD was observed in 28/39 patients with 
FBXW7 mutations and 133/235 patients without FBXW7 mutations (p=0.08; Table 3.3). 
The predictive value of FBXW7 mutations was lost at long-term outcome; both groups have a 
similar pEFS (76% in the FBXW7 mutated group versus 81% in the FBXW7 non-mutated group) 
(p=0.48; Figure 3.4A) and a similar pCIR (10% compared to 13%, p=0.6, Figure 3.4B). 
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Prednisone Response (Day 8) * 
  PPR (%) PGR (%) Data not available P‡ 
FBXW7 mutated 5 (12) 37 (88) 0 p=0.00003 
FBXW7 non-mutated 114 (45) 138 (55) 7   
          
MRD (Day 33) † 
  Unfavourable (%) Favourable (%) Data not available P‡ 
FBXW7 mutated 23 (59) 16 (41) 3 p= 0.03 
FBXW7 non-mutated 174 (76) 54 (24) 31   
          
MRD (Day 78) † 
  Unfavourable (%) Favourable (%) Data not available P‡ 
FBXW7 mutated 11 (28) 28 (72) 3 p=0.08 
FBXW7 non-mutated 102 (43) 133 (57) 24   
 
 
Table 3.3 FBXW7 mutations associate with excellent prednisone response, but have only marginal 
effects on MRD kinetics. 
* PPR: ≥1000 leukaemic blood blasts/μL on treatment day 8; PGR: <1000/μL.  
† Unfavourable MRD: ≥10-4; Favourable MRD: <10-4.  
‡ P-value; Fisher’s Test. 
 
 
 
 
Figure 3.4 FBXW7 mutations do not associate with better long-term outcome in T-ALL.  
(A) Kaplan-Meier estimate of the probability of event-free survival (pEFS) in FBXW7 
mutated and FBXW7 non-mutated patients. (B) Cumulative incidence of relapse (pCIR) in 
FBXW7 mutated and FBXW7 non-mutated patients. 
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In summary, the data indicate that FBXW7 mutations confer a high sensitivity to very early 
treatment in the ALL-BFM 2000 protocol (administration of prednisone (or dexamethasone) and 
intrathecal methotrexate). In contrast, they do not affect the response to drugs used later on 
during induction, intensification and re-induction. 
  
3.1.5 The combination of NOTCH1 and FBXW7 mutations results in excellent early treatment 
response but does not signify  a more favourable long-term outcome 
It was previously observed that FBXW7 mutations and NOTCH1-PEST mutations are 
mutually exclusive. In our cohort only one out of 30 patients showed this combination. This 
almost complete mutual exclusivity suggests that no additional selective advantage is provided by 
a NOTCH1-PEST and FBXW7 double mutation and that the biological function in T-ALL of both types 
of mutation is similar. 
In adult T-ALL, it has already been reported that FBXW7 mutations add significant prognostic 
value to NOTCH1 mutational status. It is therefore possible that both types of mutations may 
synergise clinically, also in the context of the paediatric ALL-BFM study.  
Prednisone response was available for 294 patients from the total cohort. Twenty-eight out of 30 
(93%) patients with NOTCH1 and FBXW7 mutations showed a PGR compared to 74/139 (62%) in the 
NOTCH1 mutated only group and 9/12 (75%) in the FBXW7 mutated only group. Only 64/133 (48%) of 
cases with no mutations in NOTCH1 or FBXW7 presented a PGR. 
On day 33, the group with double mutations had the highest number of cases with a favourable 
MRD (16/29; 55%) compared to the NOTCH1 mutated group with 31/109 (28%) patients and the 
group without mutations with 23/119 (19%). Conversely all 10 cases with only FBXW7 mutations 
showed unfavourable MRD. On day 78, the lowest MRD loads were present in the groups with 
mutations in both genes (24/30; 80%) and with NOTCH1 mutations alone (79/110; 72%). Four out of 
9 patients with only FBXW7 mutations (44%) and 54/125 (43%) patients with neither mutation 
showed a favourable MRD (Table 3.4).  
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Prednisone Response (Day 8) * 
  PPR (%) PGR (%) Data not available P‡ 
NOTCH1+FBXW7 
mutated 
2 (7) 28 (93) 
 
0 
 
p<0.00001 
NOTCH1 
mutated 
45 (38) 74 (62) 1 
      p=0.03 
FBXW7 
mutated 
3 (25) 9 (75) 0 
          p=0.13    
NOTCH1/FBXW7 
non-mutated 
69 (52) 64 (48) 6               
          
MRD (Day 33) † 
  Unfavourable (%) Favourable (%) Data not available P‡ 
NOTCH1+FBXW7 
mutated 
13 (45) 16 (55) 
 
1 
 
p=0.0003 
NOTCH1 
mutated 
78 (72) 31 (28) 11 
     p=0.12 
FBXW7 
mutated 
10 (100) 0 (0) 2 
          p=0.21 
NOTCH1/FBXW7 
non-mutated 
96 (81) 23 (19) 20   
          
MRD (Day 78) † 
  Unfavourable (%) Favourable (%) Data not available P‡ 
NOTCH1+FBXW7 
mutated 
6 (20) 24 (80) 
 
 0 
 
p=0.0004 
NOTCH1 
mutated 
31 (28) 79 (72) 10 
     p=0.00001 
FBXW7 
mutated 
5 (56) 4 (44) 3 
           p=1.00 
 
NOTCH1/FBXW7 
non-mutated 
71 (57) 54 (43) 14   
 
 
Table 3.4 The combination of NOTCH1 and FBXW7 mutations result in an excellent prednisone 
response and early but not late MRD. 
* PPR: ≥1000 leukaemic blood blasts/μL on treatment day 8; PGR: <1000/μL.  
† Unfavourable MRD: ≥10-4 ; Favourable MRD: <10-4.  
‡ P-value; Fisher’s Test. 
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The groups with mutations in both genes and NOTCH1 mutations alone show similar event-free 
survival (83% versus 88%) and relapse rates (8% versus 6%). The group of patients with FBXW7 
mutations includes only 12 patients, and therefore does not allow meaningful statistics. This 
group shows a poor long-term outcome (pEFS 58%) with 5 non-relapse events, and only 1 relapse. 
In terms of relapse rates, the groups with NOTCH1 or FBXW7 mutations do not show statistically 
significant differences. Patients with no mutations show a pEFS of 75%, and a high pCIR of 18% 
(21/139; Figure 3.5). 
 
 
Figure 3.5 NOTCH1 and FBXW7 mutations do not act together to predict a favourable long-term 
outcome.  
(A) Kaplan-Meier estimate of the probability of event-free survival (pEFS) in 
NOTCH1+FBXW7 mutated (dark blue), NOTCH1 mutated (red), FBXW7 mutated (green) and 
NOTCH1/FBXW7 non-mutated (light-blue) patients. (B) Cumulative incidence of relapse 
(pCIR) in NOTCH1+FBXW7 mutated (dark blue), NOTCH1 mutated (red), FBXW7 mutated 
(green) and NOTCH1/FBXW7 non-mutated (light blue) patients.   
 
In summary, NOTCH1 and FBXW7 mutations synergise clinically during early treatment response in 
the ALL-BFM 2000 treatment protocol. In contrast, FBXW7 mutations do not add predictive value 
to the NOTCH1 mutations at long-term outcome of paediatric T-ALL patients. 
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3.2 NOTCH1 and FBXW7 mutations in paediatric T-ALL at relapse  
 
Having shown in the previous part that, at initial presentation, NOTCH1 mutations, but not 
FBXW7 mutations, correlate with good prognosis in T-ALL, it was now analysed if these mutations 
associate with long-term outcome at relapse. 
 
3.2.1 Clinical characteristics of the cohort of relapsed T-ALL patients 
In the cohort of 301 T-ALL patients analysed at initial diagnosis (Figure 3.1), 35 had a 
relapse (Figure 3.2B). From these 35 children, relapse material was available in 23 cases. In 
addition, 21 patients with a relapse were analysed (Figure 3.6A). The total relapse cohort (n=34) 
was treated at initial presentation according to the ALL-BFM 2000 protocol and at relapse 
according to the ALL-REZ 2002 protocol (including the corresponding pilot protocol). To 
determine if this cohort is a representative relapse group, the clinical characteristics of the 34 
ALL-REZ 2002 treated patients were compared to the relapsed patients from the first 
presentation study (n=35; Figure 3.2). Striking is the inclusion of only 18/34 (53%) very early 
relapses in the analysed cohort, whereas the very early group from the ALL-BFM 2000 
represented 74% (26/35; Figure 3.6B). This recruitment bias was probably based on the very early 
T-ALL relapses not being treated according to the ALL-REZ protocol, but only in a palliative 
fashion. Another discrepancy was the presence of 8 (23%) patients that developed recurrent 
disease after allogeneic BMT (bone marrow transplantation) in the ALL-BFM group, compared to 
none of the patients in the analysed cohort. Most relapsed patients with allogeneic BMT receive 
palliative care, which explains the absence of this group of patients in our relapse analysis. 
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Figure 3.6 Clinical characterisation of the cohort of T-ALL patients with a relapse. 
  (A) Venn diagram of the overlap of relapses occurring in the initial presentation study 
group (n=35, yellow, Figure 3.2) and relapses analysed in this study (n=34, blue). Twenty-
three patients with a relapse were represented in both studies (green). 
(B) Comparison of the clinical characteristics of the cohort of relapsed patients analysed in 
this study (n=34) with those of the patients with a relapse (n=35) enrolled in the ALL-BFM 
2000 study group at initial presentation (Figure 3.2B). 
* Time of relapse: very early (≤18 months after initial diagnosis), early (≥18 months after 
initial diagnosis and <6 months after completion of initial therapy), late (≥6 months after 
completion of initial therapy); 
  † On/off treatment: on (relapse during treatment of initial T-ALL); off (relapse after 
treatment of initial T-ALL); after allogeneic BMT (after allogeneic bone marrow 
transplantation). 
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3.2.2 Frequency of NOTCH1 and FBXW7 mutations in paediatric T-ALL at relapse 
First, the NOTCH1 and FBXW7 mutational status was determined in the T-ALL patient 
samples at relapse. Five out of 34 (15%) patients harboured mutations in both genes, NOTCH1 and 
FBXW7, 13 (38%) were mutated in only NOTCH1 and 2 (6%) had FBXW7 mutations only. All other 14 
(41%) did not carry any mutations in either NOTCH1, or FBXW7 (Figure 3.7A). 
When compared to the frequency of mutations at initial presentation (n=301; Figure 3.1), no major 
changes could be observed (Figure 3.7B). Intriguingly, it was previously stated (Figure 3.4B) that 
ALL-BFM 2000 treated patients, that develop a recurrent disease, are mostly NOTCH1/FBXW7 non-
mutated (24 NOTCH1/FBXW7 non-mutated compared to 11 mutated). In the relapse cohort, 
however, 59% of the patients carried mutations in either NOTCH1 or FBXW7. A plausible 
explanation for this finding could be that the cohort studied is not representative of the general 
relapse population, and a recruitment bias towards patients with mutations was introduced. 
Indeed, 19/24 (79%) relapses without NOTCH1 or FBXW7 mutations (in Figure 3.6B) were very early 
relapses. An additional explanation could be that, in non-mutated patients, new mutations were 
acquired at relapse. 
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Figure 3.7 Frequency of NOTCH1 and FBXW7 mutations in childhood T-ALL at relapse 
(A) Distribution of NOTCH1 and FBXW7 mutations in paediatric T-ALL patients at relapse.  
(B) Comparison of the frequency of NOTCH1 and FBXW7 mutations in initial presentation 
samples (n=301; Figure 3.1) and in relapse samples (n=35). 
 
 
 
 
3.2.3 At relapse, NOTCH1 or FBXW7 mutations can be lost or newly acquired 
In 23 cases, the NOTCH1 and FBXW7 mutational status could be determined in matched 
initial presentation-relapse samples. Depending on possible gains or losses of mutations, patients 
were categorised into 4 classes: no mutations at first presentation/relapse (class 1), the same 
mutation(s) at first presentation/relapse (class 2), loss of NOTCH1 or FBXW7 mutation at relapse 
(class 3) and gain of mutation at relapse, but absent at initial presentation (class 4). 
Nine T-ALL patients did not present any mutations in NOTCH1 or FBXW7 at initial presentation or at 
relapse (class 1). The same mutational status was found in 5 patients (class 2). One patient had a 
NOTCH1 and a FBXW7 mutation in the initial T-ALL, and lost the NOTCH1 mutation at relapse (class 
3). Five patients lost mutations detected at first presentation, and simultaneously acquired novel 
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mutation(s) at relapse (classes 3 and 4). Three (12.5%) cases acquired novel mutations at relapse 
without losing those from the first T-ALL (class 4) (Table 3.5). 
 
Patient 
no. 
Initial Presentation * Relapse * 
Class † 
HD-N 
HD-
C TAD PEST NOTCH1 exon9 exon10 FBXW7 HD-N 
HD-
C TAD PEST NOTCH1 exon9 exon10 FBXW7 
1 - - - - - - - - - - - - - - - - 1 
2 - - - - - - - - - - - - - - - - 1 
3 - - - - - - - - - - - - - - - - 1 
4 - - - - - - - - - - - - - - - - 1 
5 - - - - - - - - - - - - - - - - 1 
6 - - - - - - - - - - - - - - - - 1 
7 - - - - - - - - - - - - - - - - 1 
8 - - - - - - - - - - - - - - - - 1 
9 - - - - - - - - - - - - - - - - 1 
10 - - - - - + - + - - - - - + - + 2 
11 + - - - + - - - + - - - + - - - 2 
12 + - - - + - - - + - - - + - - - 2 
13 - + - - + - - - - + - - + - - - 2 
14 + - - - + + - + + - - - + + - + 2 
15 + - - - + + - + - - - - - + - + 3 
16 - - - - - + - + + - - - + - - - 3 4 
17 - + - - + - - - + - - - + - - - 3 4 
18 + ‡ - + - + - - - + ‡ - + - + - - - 3 4 
19 - + - - + - - - + - - + + - - - 3 4 
20 - - - + ‡ + - - - - - - + ‡ + - - - 3 4 
21 - - - - - - - - - - - + + - - - 4 
22 - - - - - - - - + - - - + + - + 4 
23 + - - - + - - - + - - - + + - + 4 
 
 
 
Table 3.5 List of 23 pairs of initial presentation/relapse samples with the corresponding NOTCH1 
and FBXW7 mutational status. 
* Initial Presentation/Relapse: “-” = non-mutated; “+” = mutated; 
† Class: 1 = no mutation at initial presentation and at relapse; 2 = same mutation at initial 
presentation and at relapse; 3 = loss of NOTCH1 or FBXW7 mutation at relapse; 4 = gain of 
mutation at relapse, but absent at initial presentation; 
‡ Patients with a different mutation in the same protein domain at initial presentation and 
at relapse. 
 
Classes 1 and 2 were further grouped into “NOTCH1/FBXW7 mutational status unchanged” and 
classes 3 and 4 into “NOTCH1/FBXW7 mutational status changed”. Fourteen out of 24 (61%) cases 
did not present any changes in their NOTCH1/FBXW7 mutational status; however 9 (39%) patients 
lost or acquired novel mutations at relapse. The instability of NOTCH1 and FBXW7 mutations in 
more than a third of the relapsed patients could suggest that a minor resistant sub-clone, already 
present, but undetectable at diagnosis, expands during the relapse. Another possibility is the 
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existence of a leukaemic stem cell that gives rise to a new clonogenic pool at relapse. However, 
further analyses are needed to differentiate between these hypotheses. 
 
 
3.2.4 FBXW7 mutations tend to predict poor long-term outcome in relapse T-ALL 
To test whether NOTCH1 and FBXW7 mutations have a predictive value in relapsed T-ALL, 
they were correlated with long-term survival. From the cohort of 34 patients, 29 patients were 
taken into account for long-term analysis, as they were treated according to protocol. In the 
group of 29 patients, 15 were NOTCH1 mutated and 14 NOTCH1 non-mutated. As expected, the 
survival rate was very poor in the total group. However, no difference in pEFS was observed 
between the NOTCH1 mutated and the NOTCH1 non-mutated groups (33% vs 25%; p=0.16; Figure 
3.8). 
Figure 3.8 No significant difference in long-term outcome at relapse was observed between 
patients with or without NOTCH1 mutations. 
 Kaplan-Meier estimate of the probability of event-free survival (pEFS) in NOTCH1 mutated 
and NOTCH1 non-mutated relapsed T-ALL patients. 
Patients are censored when no event occurred (relapse, no response to treatment, etc.) 
and their observation time was shorter than 7.5 years.  
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In this group, seven children carried FBXW7 mutations. Event-free survival was not significantly 
different, but a trend towards better long-term outcome of relapsed patients without FBXW7 
mutations was observed (35% and 14% in the FBXW7 non-mutated and FBXW7 mutated group, 
respectively; p=0.32; Figure 3.9). 
Figure 3.9 FBXW7 mutations show a trend towards lower event-free survival. 
  Kaplan-Meier estimate of the probability of event-free survival (pEFS) in FBXW7 mutated 
and FBXW7 non-mutated relapsed T-ALL patients. 
Patients are censored when no event occurred (relapse, no response to treatment, etc.) 
and their observation time was shorter than 7.5 years.  
 
 
 
When combining the mutational status of NOTCH1 and FBXW7, four patients harboured mutations 
in both genes, eleven contained mutations only in NOTCH1 and three had mutations only in 
FBXW7. The other eleven patients were not mutated in either NOTCH1 or FBXW7. The groups with 
NOTCH1 and FBXW7 mutations, and with NOTCH1 mutations alone showed a pEFS of 25% and 40%, 
respectively, whereas the group with no mutations in either gene had a pEFS of 32%.  Strikingly, all 
patients with FBXW7 mutations alone did not respond to the intensified treatment (p=0.028; 
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Figure 3.10). Although the statistical analysis is significant, a larger group of patients would be of 
value to strengthen the relevance of these data. 
 
Figure 3.10 Relapsed patients with FBXW7 mutations alone do not respond to the intensified 
treatment. 
  Kaplan-Meier estimate of the probability of event-free survival (pEFS) in NOTCH1+FBXW7 
mutated (violet), NOTCH1 mutated (green), FBXW7 mutated (grey) and NOTCH1/FBXW7 non-
mutated (blue) relapsed T-ALL patients. 
Patients are censored when no event occurred (relapse, no response to treatment, etc.) 
and their observation time was shorter than 7.5 years.  
 
 
In conclusion, the results obtained in this study give preliminary insights into the usefulness of 
NOTCH1 and FBXW7 mutations in predicting outcome of relapsed T-ALL patients. It would now be 
of importance to confirm these results in a larger patient group. 
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4. Results 2: Characterisation of miRNA expression in paediatric T-ALL 
NOTCH1 is mutated in over 50% of all paediatric T-ALL patients. During the last years, 
research has been focussed on the identification of downstream effects of these activating 
mutations. A yet unexplored question is whether NOTCH1 mutations affect miRNA expression. 
MiRNAs act as tumour suppressors or oncogenes and could thus be powerful downstream 
effectors. In this part of the thesis, it was explored if miRNA expression is under the control of 
NOTCH1 in paediatric T-ALL. In the first experimental setting, cell-based assays were employed to 
monitor miRNA expression upon NOTCH1 knock-down. A miRNA-specific microarray platform, 
miChip, allowed for direct analysis of miRNA expression (Castoldi et al., 2006). In a second step, 
miRNA expression in primary T-ALL patient samples was analysed depending on the NOTCH1 
mutational status of the patients.  
 
4.1 miRNA expression is dependent on NOTCH1 
Here it was analysed if the deregulation of NOTCH1 in T cell lines interfered with primary 
and mature miRNA expression. For our experiments, the CCRF-CEM T cell line was chosen 
because of its high endogenous NOTCH1 expression.  Knock-down of NOTCH1 was established by 
using 5 different shRNAs targeting the mRNA of NOTCH1. Two shRNAs (shRNA2, shRNA3) were 
selected for further experiments on the basis of the highest knock-down efficiency. A non-target 
shRNA (scramble) was used as a negative control. To monitor the transduction efficiency, 
TurboGFP™ expression was measured. The shRNAs and TurboGFP™ were cloned in the lentiviral 
vector pLKO.1. 
 
4.1.1 Knock-down of NOTCH1 decreases proliferation of a T cell line 
After transduction, cells were harvested at 2 different time-points (72h and 120h). Firstly, 
NOTCH1 mRNA expression was analysed to determine the knock-down efficiency. NOTCH1 mRNA 
levels were decreased upon NOTCH1 knock-down, by approximately 45% after 72h and by 65% 
after 120h for both shRNAs (Figure 4.1A). To determine if the decrease of NOTCH1 mRNA has 
functional effects on downstream targets, HES1 mRNA levels were analysed. The expression 
levels of HES1 mirrored the NOTCH1 mRNA levels with a 40% decrease at 72h, and 50% at 120h 
(Figure 4.1B). 
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Figure 4.1 NOTCH1 knock-down decreases NOTCH1 and HES1 mRNA levels.  
(A) NOTCH1 mRNA expression and (B) HES1 mRNA expression were detected by qPCR in 
CCRF-CEM cells that were transduced with either a non-target shRNA virus (scramble) or a 
NOTCH1 shRNA (shRNA 2, shRNA3) virus targeting the mRNA of NOTCH1, at 72h and 120h 
post-transduction. 
The scramble sample was set to 1 (n=3; p<0.05 *; p<0.01 **; p<0.001 ***). 
 
Protein levels could not be analysed due to insufficient protein material available for western blot. 
In parallel to mRNA expression analysis, the cell proliferation was measured at 3 different time 
points by counting the cells with the Neubauer counting chamber (72h, 120h, 168h) (Figure 4.2). 
The expression of shRNA2 and shRNA3 had drastic effects on the proliferation rates of CCRF-CEM. 
At 168h, the cell number diminished by 40% and by 60% upon NOTCH1 knock-down using shRNA2 
and shRNA3, respectively. Altogether, these data show that the NOTCH1 knock-down is 
functional, and that NOTCH1 is essential for growth of CCRF-CEM. 
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Figure 4.2 NOTCH1 knock-down decreases proliferation in the CCRF-CEM cell line.  
The scramble sample (non-target shRNA) was set to 1. (n=6; p<0.01 **; p<0.001 ***) 
 
4.1.2 MiRNAs are differentially expressed upon NOTCH1 knockdown  
Next, it was examined if the NOTCH1 knock-down caused changes in the miRNA 
expression. Mature miRNA expression was monitored by miChip, a miRNA-specific microarray 
platform, and miQPCR, a miRNA-specific qPCR (Castoldi et al., 2006; Ibberson et al., 2009).  
4.1.2.1 Mature miRNAs differentially expressed upon NOTCH1 knock-down 
For monitoring mature miRNA expression, total RNA, harvested at 72h and at 120h from 
three independent NOTCH1 knock-down experiments, was hybridised on miChip. Total RNA 
extracted from the 72h time point was hybridised on miChip (9 chips), whereas total RNA from 
the 120h time point was pooled before hybridisation on miChip (3 chips). Raw data files were 
analysed using the miChip package in the Bioconductor software (Gentleman et al., 2004). 
Normalised data files were further analysed in Excel applying T-test and fold change calculations 
(Figure 4.3). Candidate miRNAs were chosen on the basis of different criteria: 
(1) the miRNA expression was significantly up- or down-regulated at 72h (p<0.02) upon 
NOTCH1 knock-down using both shRNAs (shRNA2 and shRNA3); 
(2) the same trend of regulation (up- or down-regulation at 72h) should be observed at 120h. 
Based on the above described criteria, a list of 5 candidate miRNAs was generated: miR-18a, miR-
18b, miR-181b, miR-15a and miR-491-3p. The 5 mature miRNAs were all down-regulated upon 
NOTCH1 knock-down (Figure 4.4). 
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Figure 4.3 Microarray workflow process 
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Figure 4.4 Candidate miRNAs differentially expressed upon knock-down of NOTCH1.  
(A) p-values (T-test) were calculated comparing the miRNA expression at 72h in cells 
expressing the non-target shRNA and one of the NOTCH1 shRNAs (shRNA2 or shRNA3). 
The fold change was calculated by dividing the mean of the NOTCH1 shRNA samples 
(either shRNA2 or shRNA3) by the mean of the non-target shRNA samples (see Figure 4.3).  
(B) Heat map of expression levels of the candidate miRNAs. The colour scale represents 
the ratios (scramble set to 1) ranging from 0 (green) to 1 (red). 
 
In parallel, a second normalisation method, vsn (variance stabilisation normalisation) (Huber et 
al., 2002), was applied (in cooperation with Wolfgang Huber, EMBL). The application of this 
alternative normalisation method showed that the miRNA expression profiles of the cells 
expressing either a NOTCH1 shRNA or a non-target shRNA were very similar (Figure 4.5), and no 
miRNA could be identified that was significantly de-regulated upon NOTCH1 knock-down. 
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Figure 4.5 Heat map of vsn-normalised miRNA expression 
 The colour scale represents the log normalised intensities ranging from 2 to 17. The left 
shows the different experiments at 72h. The right panel represents the hierarchical 
clustering of the experiments. The x-axis shows all human miRNAs of the miChip (in 
collaboration with Wolfgang Huber). 
 
To validate the miRNA expression using a second technique, a miRNA-specific qPCR approach 
(miQPCR) was used. The five candidate miRNAs identified by the miChip-normalised microarray 
analysis (in Figure 4.4) were amplified in three independent experiments (72h). However, none of 
these miRNA could be validated by the miQPCR approach (Table 4.1).  
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  shRNA2 72h shRNA3 72h 
mature miRNA p-value (T-test) Fold change p-value (T-test) Fold change 
miR-15a 0.33 1.09 fold up 0.22 1.17 fold down 
miR-181b 0.10 1.44 fold up 0.90 1.02 fold down 
miR-18a 0.34 1.16 fold down 0.13 1.63 fold down 
miR-18b 0.15 2.08 fold up 0.68 1.11 fold down 
miR-491-3p 0.81 1.09 fold up 0.09 1.34 fold down 
 
Table 4.1 miQPCR analysis of the candidate mature miRNAs from NOTCH1 knock-down 
experiments.  
The t-test was used to compare the miRNA expression in the NOTCH1 shRNA2 and shRNA3 
samples to the non-target shRNA samples. 
 
In summary, miRNA microarrays, when normalised using the miChip package in the Bioconductor 
software, could detect differentially expressed miRNAs upon NOTCH1 knock-down. However, a 
second normalisation method (vsn) showed that the miRNA signatures from cells expressing non-
target shRNAs or NOTCH1 shRNAs do not differ. A miRNA-specific qPCR confirmed the second 
normalisation method, as the qPCR results showed that the expression of five miRNAs (shown to 
be down-regulated by the miChip package) was not altered after NOTCH1 knock-down. 
 
4.1.2.2 Primary miRNA transcripts differentially expressed upon NOTCH1 knock-down 
To further analyse the effects of the NOTCH1 knock-down on miRNA expression, the 
primary transcripts of the five candidate miRNAs were examined (Table 4.2). The expression of 
the primary transcripts at 72h and at 120h was measured in three independent experiments by 
qPCR.  
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mature miRNA primary transcript 
miR-15a pri-miR-15a~16-1 
miR-181b* 
pri-miR-181a-1~181b-1 
pri-miR-181a-2~181b-2 
miR-18a  pri-miR-17~92 
miR-18b pri-miR-106a~363 
miR-491-3p pri-miR-491 
 
Table 4.2 List of candidate mature miRNAs and the corresponding primary transcripts 
* The mature miRNA miR-181b could potentially be produced by the primary transcripts, 
pri-miR-181a-1~181b-1 or pri-miR-181a-2~181b-2. 
 
Interestingly, the pri-miR-17~92 and pri-miR-491 were down-regulated two-fold upon NOTCH1 
knock-down (Figures 4.6A and 4.6B), whereas the primary transcript levels of miR-181a-1~181b-1 
were not significantly changed (Figure 4.6C). The levels of pri-miR-181a-2~181b-2 were also down-
regulated for shRNA 2 and shRNA3 at 72h compared to the scramble shRNA, but were unchanged 
at 120h (Figure 4.6D). Pri-miR-15a~16-1 levels did not show any significant changes at 72h; only in 
shRNA3 expressing cells at 120h, the primary transcript of miR-15a~16-1 was down-regulated at 
120h (Figure 4.6E). Pri-miR-106a~363 could not be detected by qPCR. 
Altogether, significant changes in miRNA expression upon NOTCH1 knock-down could be found, 
when analysing the levels of primary transcripts of miR-17~92, miR-491 and miR-181a-2~181b-2. 
However, if these expression changes have an effect on the corresponding mature miRNA levels 
is unclear, as miRNA microarray experiments produced opposite results depending on the 
normalisation method used. The maximal decrease in pri-miRNA expression levels was two-fold, 
possibly causing only subtle changes in mature miRNA expression, which could not be detected 
by qPCR. 
In conclusion, deregulation of NOTCH1 by knock-down decreased proliferation in the T-ALL cell 
line, CCRF-CEM. Primary transcripts of pri-miR-17~92 and pri-miR-491 were down-regulated two-
fold upon NOTCH1 knock-down. Microarray experiments could detect a decrease of the 
corresponding mature miRNAs, miR-18a and miR-491-3p (2-fold and 1.5-fold, respectively). 
However, mature miRNA expression could not be validated by qPCR. 
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Figure 4.6 NOTCH1 knock-down decreases primary miRNA expression levels.  
(A) pri-miR-17~92 expression, (B) pri-miR-491 expression, (C) pri-miR-181a-1~181b-1, (D) pri-
miR-181a-2~181b-2 and (E) pri-miR-15a~16-1 detected by qPCR in CCRF-CEM cells transduced 
with either a non-target shRNA virus (scramble) or a NOTCH1 shRNA virus (shRNA 2, 
shRNA3) targeting the mRNA of NOTCH1 , at 72h and 120h post-transduction.  
The scramble sample was set to 1 (n=3; p<0.05 *; p<0.01 **; p<0.001 ***). 
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4.2 miRNA expression in primary paediatric T-ALL samples 
To explore miRNA expression in T-ALL patients, primary T-ALL samples were collected 
either from the ALL-BFM study group or directly from different hospitals.  
4.2.1 MiRNA expression profiles show significant variations depending on the processing of 
diagnostic peripheral blood and bone marrow samples  
Forty-one different paediatric T-ALL samples, as well as 3 adult T-ALL and 4 preB-ALL 
samples were collected. Thirty-one T-ALL specimens originated from the sample bank of the ALL-
BFM study group. After collection of bone marrow from the patient at the hospital, the samples 
were sent by regular mail to the study centre, where they were frozen in 10% DMSO and stored in 
liquid nitrogen until further usage. These RNA samples were referred to as “frozen” samples. All 
other ALL samples corresponded to fresh peripheral blood or bone marrow samples. Within thirty 
minutes after sample collection, leukaemic blasts were prepared by Ficoll gradient analysis, 
resuspended in TRIzol® and immediately frozen. These samples are named “fresh” samples. After 
shipment to our institute on dry ice, total RNA was extracted. In addition, total RNA of 
lymphocytes extracted from a buffy coat was added as controls to the hybridisations. 
Importantly, two different RNA extraction methods were employed in this study, the TRIzol® 
extraction method and a column-based method (miRNeasy protocol, Qiagen). Those RNA 
samples extracted by the TRIzol® method are marked by an asterisk (*) in Figure 4.8. 
Because one hybridisation includes a maximum of 24 samples, the ALL specimens were 
distributed into three sets as follows: 
- Set1: 22 “frozen” paediatric T-ALL samples 
- Set2: 9 “frozen” paediatric T-ALL samples and 1 “fresh” paediatric T-ALL sample 
- Set3: 10 “fresh” paediatric T-ALL samples (1 patient represented by 2 RNA samples 
extracted by 2 different extraction methods), 3 “fresh” adult T-ALL samples and 4 “fresh” 
paediatric preB-ALL samples. 
Each hybridisation included two (set1) or three (set2 and 3) lymphocyte control samples. After 
hybridisation and data acquisition of the chips, “miChip” normalisation was applied. The median 
of the signal intensities of the lymphocyte samples were calculated for each hybridisation (hyb) 
was calculated and each ALL patient sample was divided by this median. When, in most samples, 
no data was available for a probe set, the corresponding miRNA set was removed. This left a total 
of 426 miRNAs for final analysis (Figure 4.7). The data were uploaded into TIGR MeV 4.0 for 
hierarchical clustering (HCL). 
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Figure 4.7 Analysis of the diagnostic ALL microarray data before hierarchical clustering 
 
Upon hierarchical clustering, two major clusters formed representing mostly the “fresh” and the 
“frozen” samples (Figure 4.8). The adult T-ALL specimens were comprised in the cohort of 
“fresh” samples in between the paediatric T-ALLs, indicating that profiles of adult and paediatric 
T-ALL samples are highly similar. Unexpectedly, one preB-ALL sample (preB-ALL4) was found in 
between the “fresh” T-ALL samples, whereas the other three preB-ALL were sufficiently distinct 
to form a separate cluster in the “fresh” cluster. This observation is consistent with the notion 
that these leukaemias correspond to different clinical entities, but indicates also that miRNA 
signatures of preB-ALL and T-ALL samples contain many similarities. Two “fresh” RNA samples 
were extracted by the column-based method (T-ALL4 and T-ALL9), whereas all other “fresh” ones 
were extracted using TRIzol® method. Their profiles are found mixed in the “fresh” cluster. In 
addition, sample T-ALL9 from the second hyb set clusters closely with the samples from the third 
set. This indicates that miRNA expression profiles were mostly affected by the pre-analytical 
handling (“fresh/frozen”) that overrides the changes introduced by the RNA extraction method 
and the different hybridisations.  
In conclusion, depending on the processing of blood or bone marrow samples, huge variations in 
the miRNA expression profiles occur. In this study, miRNA signatures alter mostly upon 
differential sample processing. However, possible differences caused in the profiles by the RNA 
extraction methods and the hybridisations would also be expected, but are overridden in these 
samples by the “fresh/frozen” signature.  
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Figure 4.8 Hierarchical clustering of 3 sets of ALL patient samples.  
The processing of patient samples introduces significant differences in the miRNA profiles. 
set1 =  22 “frozen” paediatric T-ALL samples (numbered 1-22, green) 
set2 =  9 “frozen” paediatric T-ALL samples (numbered A-I, green, underlined) and 1 
“fresh” paediatric T-ALL sample, T-ALL9 (black, underlined)  
set3 =  9 “fresh” paediatric T-ALL samples (black), 3 “fresh” adult T-ALL samples (dark 
blue) and 4 “fresh” paediatric preB-ALL samples (light blue).  
* Classical TRIzol® RNA extraction.  
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4.2.2 Differentially expressed miRNAs in patients with or without NOTCH1 mutations 
The microarray analysis of the T-ALL patient samples, using the miChip package, showed 
that the differential sample processing severely affects miRNA signatures. Therefore, it was not 
possible to search for miRNAs that are differentially expressed depending on clinical or biological 
characteristics. To allow the identification of miRNAs that are differentially expressed in patients 
with (n=16) or without NOTCH1 mutations (n=24), a different normalisation method was applied 
(in collaboration with Julia Engelmann, Regensburg and Wolfgang Huber, EMBL). For 1 patient, 
the NOTCH1 mutational status was not available. In this normalisation procedure, a linear model 
was introduced that eliminates effects of the batches of hybridisation and of the differential pre-
analytical handling. The analysis identified 10 candidate miRNAs that were differentially expressed 
in patients with or without NOTCH1 mutations: miR-223, miR-181a, miR-181b, miR-221, miR-191, miR-
768-5p, miR-181c, miR-19a, miR-181d and miR-518e*/519a*/519b-5p/519c-5p/522*/523* (Figure 4.9). 
It has to be noted that the differences of the median intensities in the NOTCH1 mutated and non-
mutated groups were modest. With the exception of miR-518e*/519a*/519b-5p/519c-5p/522*/523*, 
these miRNAs showed a higher expression in the patients without NOTCH1 activating mutations. 
Interestingly, a member of the miR-17~92 cluster, miR-19a, as well as, members of the miR-181 
family were amongst the candidates, that were also described in the NOTCH1 knock-down 
experiments (Figure 4.4). In contrast to the cell-based assay experiments, the miRNAs showed a 
higher expression in the NOTCH1 non-mutated group, whereas upon NOTCH1 knock-down in the 
cell line, these miRNAs were down-regulated. These opposite results await further analysis, and 
will be discussed in the following chapter. 
The validation of the expression of individual miRNA in the T-ALL patient samples was not 
possible, because of the microarray normalisation procedure. To validate these miChip data by 
another approach, another high-throughput format would be required that allows a similar 
normalisation method than the linear model for the miChip data. 
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Figure 4.9 Candidate miRNAs differentially expressed in T-ALL patients with or without NOTCH1 
mutations. 
  NOTCH1 mutated 
  NOTCH1 non-mutated 
 Median of the NOTCH1 mutated group after including the hybridisation and the 
”fresh/frozen” effects 
 Median of the NOTCH1 mutated group after including the hybridisation and the 
”fresh/frozen” effects 
 Median of the NOTCH1 mutated group before including the hybridisation and the 
”fresh/frozen” effects 
 Median of the NOTCH1 mutated group before including the hybridisation and the 
”fresh/frozen” effects 
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In conclusion, miRNA members of the mir-17~92 cluster and of the miR-181 family were found to 
be differentially expressed depending on the NOTCH1 mutational status in paediatric T-ALL 
patients. In addition, the analysis of these patient samples showed that differential sample 
processing can significantly interfere with the miRNA expression profiles. However, the effects of 
variable pre-analytical handling and data generation can be levelled out using a linear model 
during the normalisation procedure.  
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5. General Discussion and Conclusions 
 
5.1 Molecular markers in risk stratification in paediatric T-ALL 
 
A way of improving treatment outcome in patients with leukaemia is to successfully 
stratify the patients according to risk. In paediatric T-ALL, the aim of personalised treatment 
strategies are an improvement of the survival rate of high risk patients, but also a decrease of 
treatment-dependent toxicity in low risk patients. The current risk stratification protocol in the 
ALL-BFM 2000 is based on the response to induction therapy, assessed by the measurement of 
prednisone response and MRD kinetics (Conter et al., 2010). This method of risk assessment has 
been the most powerful tool to predict long-term outcome in childhood T-ALL. However, it would 
be favourable to treat the patients according to their risk at the earliest stage of the disease. 
Therefore, there is great interest in identifying clinical or molecular prognostic markers that allow 
individualised treatment already at diagnosis. 
In this study the clinical application of two potential molecular risk factors was characterised in 
paediatric T-ALL: point mutations in NOTCH1 and FBXW7, and miRNA expression profiles.  
 
5.1.1 Mutations in the NOTCH pathway to predict long-term outcome in T-ALL? 
 
5.1.1.1 Outcome prediction using mutations in the NOTCH pathway is treatment-dependent 
In this study, the NOTCH1 and FBXW7 mutational statuses were analysed for their possible 
application in risk stratification in T-ALL. The advantage of these mutations is their high frequency 
in childhood T-ALL, with over 50% of the patients containing NOTCH1 mutations and up to 20% 
harbouring FBXW7 mutations, and the simple and fast detection by sequencing. 
At initial presentation, NOTCH1 mutations strongly predict better early treatment response and 
improved long-term outcome (Table 3.1; Figure 3.2). This effect was restricted to the standard and 
intermediate risk groups, whereas in the high risk group similar survival rates were observed for 
patients with and without NOTCH1 mutations (Figure 3.3). Study groups with similar treatment 
strategies also observed the positive effect of NOTCH1 mutations on treatment outcome (Asnafi 
et al., 2009; Malyukova et al., 2007; Park et al., 2009). However, in other groups no association 
was described between NOTCH1 mutations and long-term outcome (Baldus et al., 2009; Larson 
Gedman et al., 2009; Mansour et al., 2009; van Grotel et al., 2008; Zhu et al., 2006; Zuurbier et al., 
2010). These results suggest that the effect of NOTCH1 mutations depends on the treatment 
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protocol applied. It is known from other cancer types that markers can be treatment-dependent 
(p16INK4A and Bcl-2 expression in prostate cancer (Lopergolo and Zaffaroni, 2009) or microvessel 
count in breast cancer (Esteva and Hortobagyi, 2004)). Therefore, the clinical utility of prognostic 
factors has to be rigorously validated for each treatment protocol. 
The reason why patients with NOTCH1 mutations respond particularly well to the ALL-BFM 
protocol is currently unknown. Because treatment protocols use multi-agent therapies and vary in 
the nature of the drugs and the corresponding doses administered, a simple comparison between 
protocols will not be possible to identify the agent(s) that induce a positive response in the 
NOTCH1 mutated group. However, an indication towards a favourable treatment strategy for the 
NOTCH1 group came from the comparison between our ALL-BFM 2000 study and the EORTC study 
group (Clappier et al., 2010). The chemotherapy in the EORTC protocol is in large parts similar to 
the ALL-BFM protocol, but does not include cranial irradiation. Interestingly, in the EORTC study 
group, NOTCH1 mutated patients were characterised by a better response to the prephase and 
higher incidence of low MRD level than the patients without NOTCH1 mutations. In contrast to the 
ALL-BFM, however, the long-term outcome of T-ALL patients with or without NOTCH1 mutations 
was similar (Clappier et al., 2010). In particular, the NOTCH1 mutated group treated according to 
the high risk protocol showed a poor prognosis in long-term outcome. (pEFS of 0% and 42%, 
respectively; Figure 5.1; Clappier et al., 2010). They also identified a non-significant trend towards a 
higher number CNS relapses in the NOTCH1 mutated group, which are generally rare in the ALL-
BFM 2000 study. It could be hypothesised that in the ALL-BFM 2000, cranial radiotherapy 
prevents CNS relapses in the high risk patients with NOTCH1 mutations and thereby improve 
overall outcome of this group. Because of the radiation-associated late complications, such as 
second malignancies and decline in growth rate (Sklar et al., 1993; Walter et al., 1998), concerns 
have been raised about the use of prophylactic cranial irradiation in childhood ALL. The 
occurrence of these late sequelae led to omission of cranial radiotherapy or dose reduction in 
some protocols (Conter et al., 1997; Kamps et al., 1999; Pui et al., 2009). Therefore, the 
comparison of the ALL-BFM 2000 and EORTC study groups is of great importance, because it led 
to the possible identification of a patient group that could truly benefit from cranial irradiation. 
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Figure 5.1 Event-free survival of T-ALL patients in EORTC-CLG trials according to NOTCH1/FBXW7 
mutations in patients with high MRD level (>10-2) (with the permission of Clappier et al.) 
Patients without NOTCH1 and FBXW7 mutations (with high MRD level) had a better EFS 
than the patients with NOTCH1 or FBXW7 mutations (0% vs 42%; p=0.05; Clappier et al., 
2010). 
  
 
In accordance with the higher rate of CNS relapses in the EORTC-treated NOTCH1 mutated group, 
is the finding in a T-ALL mouse model that NOTCH1 causes CNS involvement via controlling the 
expression of CCR7 (Buonamici et al., 2009). The chemokine receptor, CCR7, and its ligand, CCL19 
expressed in brain epithelial cells, are essential for CNS infiltration by the leukaemic T cells. CCR7 
is a key regulator of the immune system, demonstrated by migrating defects of the immune cells, 
including T cells, into the lymph nodes and the ineffective tolerance to self-antigens leading to 
multi-organ autoimmunity in CCR7-deficient mice (Davalos-Misslitz et al., 2007; Schneider et al., 
2007). The role of CCR7 in CNS involvement in human T-ALL is currently unknown. A more detailed 
understanding of the mechanism of CCR7-induced CNS infiltration could pave the way for new 
treatment strategies of CNS-directed therapy. In addition, the detection of CCR7 expression at 
diagnosis could provide a potential predictive value for CNS involvement.  
 
5.1.1.2 Patients with NOTCH1 and FBXW7 mutations respond differently to treatment  
Because FBXW7 is part of the NOTCH pathway, it was hypothesised that patients with 
FBXW7 mutations respond similarly to the ALL-BFM treatment than those with NOTCH1 mutations. 
In addition, NOTCH1-PEST and FBXW7 mutations are found in a mutual exclusive manner (with the 
exception of 1 out of 301 patients), suggesting that no additional selective advantage is offered by 
mutating both proteins that target the same degradation pathway. Indeed, early treatment 
response (assessed by prednisone (or dexamethasone) response) was excellent in patients with 
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FBXW7 mutations. Unexpectedly however, late MRD kinetics and pEFS were not significantly 
different between the FBXW7 mutated and non-mutated groups. Therefore, it seems that the 
effect of both types of mutations is separable. A possible explanation could be that FBXW7 
interferes with other oncogenic pathways and proteins like c-MYC, PSEN1, c-JUN, cyclin E1, SREBP, 
mTOR or Aurora-A (Koepp et al., 2001; Li et al., 2002; Mao et al., 2008; Nateri et al., 2004; 
Sundqvist et al., 2005; Yada et al., 2004). In line with this, is the fact that NOTCH1 mutations are 
specifically found in T-ALL, whereas FBXW7 mutations have been identified in many different 
tumour types raising the hypothesis of NOTCH-independent effects of FBXW7 mutations 
(Rajagopalan et al., 2004; Spruck et al., 2002). The mutual exclusiveness of NOTCH1-PEST and 
FBXW7 mutations, however, suggests that FBXW7 primarily targets NOTCH1 as a means of 
activating NOTCH1 signalling.  As a “side effect” of inactivating mutations of the E3 ubiquitin 
ligase, the half-life of other FBXW7 targets could be affected, and explain the different response 
to treatment of patients with FBXW7 mutations. 
Of particular interest for individualised treatment, are patients with isolated FBXW7 mutations 
that show a particularly low pEFS at initial presentation (58%; n=12; Figure 3.5) and at relapse (0%; 
n=3; Figure 3.10). Although the low number of patients does not allow meaningful statistics, the 
analysis of a larger cohort could potentially identify a group of high risk patients. Nevertheless, 
due to the diversity of events in this group (1 second malignancy, 3 deaths before or in complete 
remission, 1 relapse at initial presentation; 2 “non-response to treatment”, 1 death before CR at 
relapse), it would be difficult to define a uniform therapy for this heterogeneous group.  
In contrast to FBXW7 mutations, NOTCH1 mutations correlate with a good prognosis of outcome. 
This effect is however restricted to the SR/MR groups, and no difference in EFS was observed in 
the HR group (Figure 3.3). The events in the NOTCH1 non-mutated group, treated according to the 
high risk protocol, were mostly relapses (18/27), whereas in the NOTCH1 mutated group, the 
number of non-relapse events was higher (including 7 deaths in CR). It can be speculated that the 
treatment was too intensive for these NOTCH1 mutated patients, and that this group might have 
benefitted from a SR or MR therapy. The validation of these data by a prospective study could 
favour the inclusion of NOTCH1 mutations as a prognostic marker in the ALL-BFM treatment 
protocol. 
 
5.1.1.3 The NOTCH pathway and the response to glucocorticoids 
As discussed previously, the mechanism of response of the NOTCH1 mutated patients to 
the ALL-BFM treatment protocol will be difficult to entangle. However, already during the early 
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prephase (administration of prednisone/dexamethasone and intrathecal methotrexate), the 
group of NOTCH1 and FBXW7 mutated T-ALLs show an excellent response to the early treatment. 
This stands in striking contrast to studies in cell-based assays and in mouse models, in which 
NOTCH1 actively induces glucocorticoid (GC) resistance (De Keersmaecker et al., 2008; Deftos et 
al., 1998). Treatment with GSI reverses this effect, and dexamethasone (a glucocorticoid) is able 
to induce apoptosis (De Keersmaecker et al., 2008; Real et al., 2009). NOTCH1-induced GC 
resistance is mediated by up-regulation of the pro-survival factor, Bcl-2 (B-cell lymphoma 2; Deftos 
et al., 1998), and of HES-1, which inhibits the transcription of the glucocorticoid receptor gene, 
NR3C1 (Real et al., 2009). A Bcl-2-independent mechanism of resistance, is the NOTCH1-mediated 
down-regulation of SRG3 (SWI3-related gene product), a component of the chromatin-
remodelling complex, SWI/SNF (SWItch/Sucrose NonFermentable) (Choi et al., 2001; Pottier et al., 
2008). How the level of SRG3 expression determines GC sensitivity remains elusive. Moreover, 
dexamethasone-induced apoptosis in lymphoma cells is prevented by GSK3 inhibition (Spokoini et 
al., 2010). GSK3 (Glycogen synthase kinase-3) causes apoptosis by interacting with pro-apoptotic 
BIM, possibly activating the mitochondrial apoptotic pathway. Inhibition of NOTCH1 signalling 
results in GSK3 inhibition via activation of Akt signalling, thus causing apoptotic sensitivity 
(Spokoini et al., 2010).   
Why glucocorticoid correlates positively with the presence of NOTCH1 or FBXW7 mutations in T-
ALLs, treated according to the ALL-BFM protocol response, remains to be investigated. The in 
vivo response in human T-ALL might be more complex as proposed in the experimental settings. 
Alternatively, NOTCH1-induced GC resistance might be present in only a subset of T-ALL patients 
(e.g. NOTCH1 mutated high risk group). This group could represent a subgroup of patients in 
whom the concomitant use of a NOTCH1 inhibitor (GSI) with glucocorticoids may be beneficial, 
sparing them from the side and late effects of intensified chemotherapy. It could also be 
speculated that the better early prephase response in the mutated group is not only related to 
the administration of glucocorticoids, but also to the administration of intrathecal methotrexate. 
 
5.1.1.4 The mechanism of T-ALL relapses  
The comparison of matched diagnosis and relapse samples unravelled the instability of 
NOTCH1 and FBXW7 mutations in approximately one third of the patients. In these patients, a gain 
or a loss of NOTCH1/FBXW7 mutations was described at relapse. This result confirms a previous 
study in which 4/16 patients showed a variable NOTCH1 mutational status in the primary and the 
recurrent leukaemia (Mansour et al., 2007). These findings raise the question about the 
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mechanism of relapse. One hypothesis for the acquisition of novel mutations is the existence of a 
leukaemic stem cell that gives rise to a new clonogenic pool at relapse (Bonnet and Dick, 1997; 
George et al., 2001). Another possibility is the selection and further expansion of a minor resistant 
sub-clone that was already present, but undetectable, at diagnosis (Choi et al., 2007; Li et al., 
2003; Mullighan et al., 2008). To differentiate between these hypotheses (Figure 5.2), additional 
leukaemic-specific characteristics need to be analysed, such as TCR rearrangements or 
chromosomal aberrations. From a clinical perspective, the detection of minor resistant clones at 
first presentation would allow an additional way to improve T-ALL therapy, by intensification of 
the treatment at initial diagnosis.  
 
 
 
Figure 5.2 Two alternative models for T-ALL relapse 
(A) The relapse clone develops from a leukaemic stem cell (LSC). 
(B) During treatment of the first T-ALL, resistant leukemic cells are selected. 
 
 
5.1.1.5 NOTCH pathway mutations as MRD markers? 
 In the ALL-BFM 2000 study group, MRD measurements are DNA-based. This is achieved 
through leukaemic clonal specific detection and amplification of Ig and TCR gene rearrangements 
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by quantitative PCR. Due to the clonal evolution of Ig and TCR gene rearrangements, at least two 
sensitive MRD markers are analysed to prevent false-negative MRD (Szczepanski et al., 2002b). 
The relatively high frequency of NOTCH1 and FBXW7 mutations in paediatric T-ALL makes them 
potential MRD marker candidates. However, a downside of the use of these mutations is the lack 
of their stability at relapse (Table 3.5). Although NOTCH1 is a key player in the pathogenesis of T-
ALL and is a potent inducer of leukaemia in mice (Pear et al., 1996), the activating mutations can 
also occur as secondary events (Chiang et al., 2008; Lin et al., 2006; Mansour et al., 2007; O'Neil et 
al., 2006). Consequently, the mutational status of NOTCH1 would not be sufficiently reliable to 
serve as a sole MRD marker, with the uncertainty of missing NOTCH1-independent leukaemic 
clones. 
 
5.1.2 mRNA and miRNA expression profiling to predict long-term outcome in T-ALL? 
In recent years, many expression profiles have been analysed with success to identify 
different cancer types or clinical subtypes of the same entity (Calin et al., 2004a; Golub et al., 
1999; Lu et al., 2005). Gene expression profiling provided a new approach for defining new 
tumour subtypes, and for assigning samples to already defined subclasses (Golub et al., 1999; 
Ross et al., 2004; Yeoh et al., 2002). Moreover, matched first diagnosis-relapse samples could 
identify differences in gene expression at relapse (Staal et al., 2003; Yeoh et al., 2002). The 
comparison of first diagnosis samples from patients that were in CR or relapsed, allowed the 
prediction of recurrent disease development. In addition, patients with a different treatment-
response or characterised by drug resistance showed different patterns in gene expression (Cario 
et al., 2005; Cheok et al., 2003; Holleman et al., 2004; Lugthart et al., 2005; Moos et al., 2002). 
In paediatric T-ALL, Ferrando et al. described different mRNA expression profiles that were 
indicative of the arrest in the developmental stage (Ferrando and Look, 2003). Each group with 
similar expression patterns was characterised by aberrant expression of a known oncogene in T-
ALL. Importantly, the gene expression signatures were of clinical relevance as, for example, the 
group with high HOX11 expression was associated with favourable prognosis. T-ALL samples could 
be distinguished with high accuracy from preB-ALL samples by comparing expression signatures 
of a subset of genes (Fulci et al., 2009; Haferlach et al., 2005; Moos et al., 2002; Yeoh et al., 2002). 
As miRNA expression profiles have also shown to be useful for subtype classification, risk 
stratification or prognosis (Calin et al., 2005; Fulci et al., 2009; Lu et al., 2005), miRNA profiling 
was undertaken in this study using 40 paediatric T-ALL samples obtained from different hospitals 
and institutes in Germany. Peripheral blood or bone marrow samples were either sent to the ALL-
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BFM study centre for storage in the sample bank or directly stored in trizol after collection from 
the patient. Differential pre-analytical sample processing caused major changes in the miRNA 
expression signatures, overriding possible biological differences resulting from the arrest in a 
specific developmental stage, expression of oncogenes or point mutations. Similar variation due 
to pre-analytical handling is expected in mRNA expression signatures (Breit et al., 2004; Micke et 
al., 2006; Schoenberg Fejzo and Slamon, 2001). Therefore, careful pre-analytical handling needs to 
be guaranteed to obtain comparable and meaningful expression profiles. To date however, it 
would be practically impossible to apply the techniques in the setting of a multi-centre study, due 
to difficulties in homogenous sample processing and due to the long-lasting experimental set-up. 
Major criteria for microarray studies in a multi-centre study include short and cold storage of 
patient material, purification of leukaemic cells, identical RNA extraction method and microarray 
protocol/platform/analysis (Staal et al., 2006; Staal et al., 2003).  
In summary, although mRNA and miRNA expression profiles could be powerful predictors of risk 
in paediatric T-ALL, their application harbours major difficulties ranging from pre-analytical 
handling to tedious data generation. Therefore, the application of genomic markers such as point 
mutations would be favoured for fast and simple risk assessment in a clinical setting. 
 
5.1.3 Towards a molecular risk profile in paediatric T-ALL? 
 
Although NOTCH1 mutations predict improved long-term outcome in paediatric T-ALL 
patients, there is substantial overlap between poor and good responders in the NOTCH1 non-
mutated group. To more stringently identify high risk patients with increased risk for relapse, 
additional markers are needed. Multiple risk factors could be combined into a molecular risk 
profile determined at the time of diagnosis. Attractive factors could be chromosomal aberrations, 
(such as deletions or gains of specific chromosomal regions), point mutations or expression 
levels.  
Interesting candidate markers are CASP8AP2 gene deletions predicting unfavourable treatment 
response in ALL-BFM 2000 (12% in paediatric T-ALL; Remke et al., 2009) and PTEN inactivating 
mutations/deletions (between 5-25% of T-ALL patients; Maser et al., 2007), that were shown to 
have a negative prognostic impact in the GBTLI ALL-99 study (Jotta et al., 2010) and in a combined 
study of the Children's Oncology Group 9404 and Dana-Farber Cancer Institute 00-001 clinical 
trials (Gutierrez et al., 2009). In contrast, the Pediatric Oncology Group (POG) study group failed 
to associate the PTEN inactivation with treatment outcome (Larson Gedman et al., 2009). In the 
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Children's Oncology Group 9404 and Dana-Farber Cancer Institute 00-001 study groups, also LEF1 
micro-deletions were analysed that showed a trend towards better overall survival (Gutierrez et 
al., 2010). Other point mutations include WT1 inactivating mutations (found in approximately 15% 
of the paediatric T-ALLs). However, the EORTC study group (Renneville et al., 2010), as well as the 
DCOG and the COALL-97 groups (Tosello et al., 2009) did not observe a prognostic significance of 
these mutations in their cohorts. A recent study on PHF6 (PHD finger protein 6) mutations 
(identified 16% in paediatric T-ALLs) did not detect an association with patient outcome treated 
according to the DCOG protocols (Van Vlierberghe et al., 2010).  
Although the assessment of mRNA expression levels is more difficult compared to the 
assessment of genomic markers (see 5.1.2), the expression of T-ALL oncogenes shows prognostic 
relevance in a number of studies. Indeed, high HOX11 expression levels correlates with good 
prognosis in T-ALL, whereas HOX11L2 is mostly associated with a poor outcome (Ballerini et al., 
2002; Bergeron et al., 2007; Cave et al., 2004; Ferrando et al., 2002).  
In sum, the collection of several prognostic markers could potentially result in accurate risk 
stratification and in an appropriate treatment strategy for each newly diagnosed T-ALL patient. 
 
5.2 The role of miRNAs in paediatric T-ALL 
 
5.2.1 miRNA expression in T-ALL is dependent on NOTCH1 
In recent years, major advances in understanding the pathophysiology of T-ALL have been 
made. An important contribution came by Weng et al. with the discovery of activating NOTCH1 
mutations in more than 50% of the paediatric T-ALL patients (Weng et al., 2004). Some of the 
downstream effects of increased NOTCH1 signalling include the up-regulation of c-MYC 
transcription or the activation of the mTOR pathway (Chan et al., 2007; Palomero et al., 2006; 
Sharma et al., 2006). However, each downstream effect only partially explains the phenotype 
observed by aberrant NOTCH1 activation. Because an interplay between NOTCH1 and miRNAs has 
been described in development and in cancerogenesis (Wang et al., 2010), we hypothesised that 
NOTCH1 activation in T-ALL also affects miRNA expression.  
To investigate this question, a cell-based assay was set-up in which NOTCH1 expression was 
knocked down and miRNA expression was monitored by miRNA-specific microarray-based 
profiling. Interestingly, NOTCH1 down-regulation drastically decreases cell proliferation 
confirming the role of NOTCH1 in maintaining T-ALL cell growth, even in cultured cells (Palomero 
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et al., 2006; Weng et al., 2003). MiRNA signatures were analysed using two different 
normalisation methods. Using the miChip method (Castoldi et al., 2006), a number of miRNAs 
showed differential expression upon NOTCH1 knock-down. The candidate miRNAs with the 
largest changes were miR-18a, miR-18b, miR-181b, miR-15a and miR-491-3p that were all down-
regulated when NOTCH1 was knocked down. By contrast, the vsn method did not detect any 
major differences between non-target and NOTCH1 shRNA overexpression (Huber et al., 2002). To 
validate the miChip-normalised microarray data, a miRNA-specific qPCR, miQPCR, was used 
(patent application EP 09 002 587.5). However, the expression of the 5 miRNAs could not be 
recapitulated. Possible reasons include that the vsn normalisation is the more appropriate 
method for normalisation. Contrasting this view, expression analysis of the primary transcripts 
indicated that both, the transcripts coding for the miR-17~92 cluster and miR-491, were down-
regulated two-fold upon 72h of NOTCH1 knock-down.  
MiRNA expression analysis in paediatric T-ALL samples (n=41) was performed with the application 
of a linear model in the normalisation procedure. This method allowed the identification of a small 
number of miRNAs differentially expressed in patients with NOTCH1 mutations. Prominent miRNA 
candidates were miR-223, members of the miR-181 family and mir-19a, a member of the miR-17~92 
cluster. Unexpectedly, miR-181 members and miR-19a showed higher expression levels in the 
NOTCH1 non-mutated group, contrasting the data of the cell-based assays.  
In the cell-based assays, highest expression differences in mature and primary miRNA expression 
were two-fold changes. These expression changes are maybe too subtle to be detected by all 
methods. The discrepancy of miRNA expression between patient samples and cell lines could be 
explained by the cell lines having compensated the effect on miRNA expression. Alternatively, 
due to the problems of pre-analytical handling, the opposite findings could be based on the poor 
quality of the patient data. An important difference between the two methods is that the cell-
based assay permitted the assessment of direct effects of NOTCH1 deregulation. In primary T-ALL 
patient samples, the NOTCH1 effect might be weakened or overridden by other clinical or 
biological differences.  
In conclusion, additional approaches could be useful to confirm the effect of NOTCH1 on miRNA 
expression, such as T-ALL mouse models. 
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5.2.2 Role of miRNAs in human T cell development 
In the past years, research groups have studied mRNA/miRNA expression in leukaemia by 
comparing profiles of patients with a different leukaemia subtype (Fulci et al., 2009; Moos et al., 
2002), with different molecular (Ferrando and Look, 2003) or clinical (Cario et al., 2005; Lugthart 
et al., 2005) characteristics. Another way to learn about aberrant miRNA expression is to compare 
profiles of primary T-ALL samples to profiles of T cell development.  
T cell development is characterised by differentiation and maturation of haematopoietic 
progenitor cells (HPCs) into mature T cells in the thymus. When HPCs enter the murine thymus, 
they undergo positive and negative selection, and progress from a double negative (DN; CD4-
CD8-) to a double positive (DP; CD4+CD8+), and finally mature to a single positive stage (SP; CD4+ 
or CD8+) (Staal et al., 2001). In T-ALL, the leukaemic blasts are characterised by a block in one of 
these stages, and the stage differs between the T-ALL patients. 
It was previously shown that expression profiling of murine and human T cell development is 
possible (Dik et al., 2005; Neilson et al., 2007). In a murine model, miRNA profiles were generated 
from different developmental stages, demonstrating a dynamic regulation of miRNAs during T 
cell development (Neilson et al., 2007). Due to difficult accessibility of human thymus, most 
studies on maturation of thymocytes were done in the mouse. However in an exploratory study, 
several distinct stages of T lymphocyte development were separated and mRNA expression 
profiling carried on each stage (Dik et al., 2005). By a qPCR and a microarray approach, TCR gene 
rearrangement could be followed through several maturation steps, and possible regulators of 
TCR recombination could be identified.  
To gain insight in deregulated miRNA expression in T-ALL, the direct comparison of T-ALL samples 
to each stage of T cell maturation would be of great interest. Furthermore, T-ALL patients could 
be accurately assigned to a particular developmental stage. This information, in turn, could be 
used to identify novel prognostic subgroups. 
 
5.2.3 The functional role of the miR-17~92 cluster and of its homologues in paediatric T-ALL 
The miR-17~92 cluster includes miR-17, miR-18a, miR-19a, miR-19b-1, miR-20a and miR-92a-1, 
whereas the miR-106~363 cluster encodes for miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92a-2, 
and miR-363 and the miR-106b~25 cluster is composed of miR-106b, miR-93 and miR-25. The 
oncogenic function of these clusters has been widely described in leukaemias and in solid 
tumours (He et al., 2005; Volinia et al., 2006).  
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Also in T-ALL, miR-17~92 was shown to play a role (Mavrakis et al., 2010). Specifically, miR-19 
delivers the oncogenic activity, and cooperates with NOTCH1 to induce T-ALL leukaemogenesis. 
The oncogenicity of miR-19 is partly driven by targeting BIM, PTEN and PPP2R5E. Interference 
with the expression of BIM, an anti-survival factor, could result in apoptosis repression, whereas 
translational repression of PTEN and PPP2R5E (subunit of PP2A), that inhibit PI3K-Akt signalling, 
could affect proliferation. Interestingly, the PI3K-Akt pathway was reported to also be up-
regulated by the activation of NOTCH1 (Palomero et al., 2007). Furthermore, frequent 
chromosomal aberrations and mutations were found in the PI3K-Akt pathway, demonstrating its 
essential role in the pathogenesis of T-ALL (Maser et al., 2007; Remke et al., 2009). Other targets 
of this cluster include E2F1, CDKN1A/p21 and Cyclin D1 identified in other human malignancies 
(Inomata et al., 2009; O'Donnell et al., 2005; Petrocca et al., 2008; Yu et al., 2008). Interesting is 
also the fact that c-MYC, a NOTCH1 transcriptional target in T-ALL, is able to activate the 
expression of miR-17~92 (O'Donnell et al., 2005). The decrease in expression of pri-miR-17~92 
observed upon NOTCH1 knock-down could be mediated by c-MYC in T-ALL. The mechanism 
behind this regulation however remains unclear and awaits further investigation. 
Moreover, a homologue cluster of miR-17~92, miR-106a~363, is highly expressed in T-cell 
leukaemia and induces anchorage independence in NIH-3T3 cells (Landais et al., 2007). Only 
recently, a molecular mechanism was discovered why boys develop T-ALL more frequently than 
girls. An X-chromosome-targeted analysis identified inactivating mutations in PHF6, a 
transcriptional regulator, that were found almost exclusively in males (Van Vlierberghe et al., 
2010). Intriguingly, the gene encoding miR-106a~363 is also located on the X chromosome. It 
could be hypothesised that the high expression of miR-106a~363 in T-cell leukaemia is caused by 
chromosomal aberrations or epigenetic changes in this chromosomal region. It remains to be 
investigated if a gender-specific role of miR-106a~363 in leukaemogenesis exists, and which 
mature miRNA in this cluster harbours T-ALL oncogenicity. 
 
5.2.4 The functional role of the miR-181 family in paediatric T-ALL 
Despite important functions in haematopoiesis and in solid tumours (Chen et al., 2004; Li 
et al., 2007; Shi et al., 2008), tumourigenic activity of the miR-181 has only scarcely been described 
(patent application WO/2009/148631; Pekarsky et al., 2006). Of particular interest is the finding 
that miR-181a is able to influence the expression of negative regulators of the NOTCH and the pre-
TCR pathways, and thereby to modulate these signalling pathways in T-ALL (patent application 
WO/2009/148631). Overexpression of miR-181a in murine double positive (DP: CD4+CD8+) 
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thymocytes induces an accumulation of DP cells, but inhibits maturation into single positive (SP) 
CD8+ thymocytes. Among miR-181a targets, are NRARP, a negative regulator of NOTCH signalling 
(Lamar et al., 2001), and multiple phosphatases, such as SHP2, involved in pre-TCR signalling 
suppression (Nguyen et al., 2006). Although in this experimental setting, miR-181c was not able to 
influence DP development, the in vivo role of the other miR-181 family members in T-ALL 
leukaemogenesis, namely miR-181b and miR-181d, needs to be determined.  
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6. Future Perspectives 
 
 
How to improve treatment strategies and survival of children and adolescents with T-cell acute 
lymphoblastic leukaemia? 
 
The use of intensive chemotherapy in the treatment protocols has contributed to the improved 
survival rates of ALL patients. Treatment failure in relapsed patients and late sequelae, however, 
mandate a search for new therapy strategies. 
A way to increase overall outcome, is a stringent risk stratification protocol that accurately 
assigns patients to different risk groups in the earliest stages of the disease. Nowadays, molecular 
markers, that could allow early risk assessment, are still missing. The search for novel markers in 
T-ALL could be very fruitful in guiding the development of very early risk-adapted therapies, as 
highlighted by this PhD study.  
In addition, the remarkable progress in understanding the pathogenesis of the disease harbours 
the possibility of developing targeted therapeutic strategies. In particular, inhibitors of the 
NOTCH pathway, such as the γ-secretase inhibitor (GSI), have been suggested. Unfortunately, the 
clinical trials of GSIs in T-ALL were hampered through severe gastrointestinal toxicity and low 
induction of apoptosis in leukaemic cells (Deangelo et al., 2006; Roy et al., 2007). In a recent study 
using a mouse model, these effects were reversed by a combination therapy of GSIs and 
glucocorticoids (Real et al., 2009). Further identification of cellular signalling pathways in T-cell 
malignancy could open new avenues for novel treatment approaches. 
 
Tailoring the intensity of treatment with the help of molecular prognostic factors, and using 
target-specific therapeutics could help in answering the above question…  
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